WO2013100570A1 - Phenyl carbamate compounds for use in preventing or treating epilesy - Google Patents

Phenyl carbamate compounds for use in preventing or treating epilesy Download PDF

Info

Publication number
WO2013100570A1
WO2013100570A1 PCT/KR2012/011474 KR2012011474W WO2013100570A1 WO 2013100570 A1 WO2013100570 A1 WO 2013100570A1 KR 2012011474 W KR2012011474 W KR 2012011474W WO 2013100570 A1 WO2013100570 A1 WO 2013100570A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbamate
group
chlorophenyl
hydroxypropyl
dichlorophenyl
Prior art date
Application number
PCT/KR2012/011474
Other languages
French (fr)
Inventor
Yong Moon Choi
Original Assignee
Bio-Pharm Solutions Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020147015403A priority Critical patent/KR101880584B1/en
Priority to AU2012360365A priority patent/AU2012360365B2/en
Priority to EP12862488.9A priority patent/EP2797880B1/en
Priority to RU2014124028A priority patent/RU2632659C2/en
Priority to MX2014008020A priority patent/MX353024B/en
Priority to BR112014015568-2A priority patent/BR112014015568B1/en
Application filed by Bio-Pharm Solutions Co., Ltd. filed Critical Bio-Pharm Solutions Co., Ltd.
Priority to CN201280070646.6A priority patent/CN104136413B/en
Priority to CA2859129A priority patent/CA2859129C/en
Priority to ES12862488.9T priority patent/ES2624989T3/en
Priority to JP2014549995A priority patent/JP6298766B2/en
Publication of WO2013100570A1 publication Critical patent/WO2013100570A1/en
Priority to IN1436MUN2014 priority patent/IN2014MN01436A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/26—Polyhydroxylic alcohols containing only six-membered aromatic rings as cyclic part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/36—Polyhydroxylic alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

  • the present invention provides a phenyl carbamate compound, a pharmaceutical composition for preventing and/or treating epilepsy comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating epilepsy.
  • Epilepsy is a chronic neurological disorder presenting a wide spectrum of diseases that affects approximately 50 million people worldwide, which corresponds to 1% of the world's burden of disease, equaling breast cancer in women and lung cancer in men. Epilepsy refers to a clinical phenomenon rather than a single disease entity, since there are many forms and causes of epilepsy.
  • An essential step in the diagnosis and treatment of a patient with a seizure is to determine the type of seizure that has occurred.
  • the main characteristic that distinguishes the different categories of seizure is whether the seizure activity is partial or generalized.
  • An embodiment provides an organic compound, i.e., phenyl carbamate compound. More particularly, the embodiment is directed to a phenyl carbamate compound of the following Chemical Formula 1 , an enantiomer or a diastereomer thereof, or a mixture of enantiomers or diastereomers; or a pharmaceutically acceptable salt of organic acid or inorganic acid thereof; which has remarkably excellent treatment effect on epilepsy as well as very low toxicity. Also, the compounds of formula I may be useful as a drug especially for the treatment of epilepsy: [Chemical Formula 1]
  • X is a halogen, for example, chlorine, fluorine, iodine, or bromine,
  • n that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2,
  • Rl is a linear or branched alkyl group of C1-C4, for example, methyl group, ethyl group, isopropyl group, or butyl group,
  • A is hydrogen or a carbamoyl derivative represented by ,
  • B is hydrogen, a carbamoyl derivative represented by ® , trialkyl silyl groups (e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), or a trialkyl silyl ether group, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group,
  • a and B are not carbamoyl derivatives at same time.
  • R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
  • Another embodiment provides a pharmaceutical composition for of preventing and/or treating epilepsy containing a compound of Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.
  • Another embodiment provides a method of preventing and/or treating epilepsy comprising administering a pharmaceutically effective amount of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of preventing and/or treating epilepsy.
  • Another embodiment provides a phenyl carbamate compound represented by Chemical Formula 1 ; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of epilepsy or the manufacture of a pharmaceutical composition for preventing and/or treating epilepsy.
  • an embodiment provides an organic compound, i.e., phenyl carbamate derivatives, more particularly, a phenyl carbamate compound represented by following Chemical Formula 1 ; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof:
  • X is a halogen, for example, chlorine, fluorine, iodine, or bromine,
  • n that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2
  • Rl is a linear or branched alkyl group of C1-C4, for example, methyl group, ethyl group, isopropyl group, or butyl group,
  • A is hydrogen or a carbamoyl derivative represented by H
  • B is hydrogen, a carbamoyl derivative represented by ⁇ ? trialkyl silyl groups (e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), or a trialkyl silyl ether group, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group,
  • TMS trimethyl silyl
  • TES
  • a and B are not carbamoyl derivatives at same time.
  • R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
  • the phenyl carbamate compound may be selected from the group consisting of:
  • the compound may not include l-(2-chlorophenyl)-l,2- propanediol, l-(2-chlorophenyl)-l-hydroxybutyl-2-carbamate, and 1 -(2,6-dichlorophenyl)- 1- hydroxybutyl-2-carbamate.
  • the compound may exist in the form of an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers, as well as a racemate.
  • the compound may be in the form of a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt may include an additional salt of acid or base, and its stereochemical isomer.
  • the compound may be in the form of an additional salt of an organic or inorganic acid.
  • the salt may not be specially limited, and include any salts that maintain the activities of their parent compounds, with no undesirable effects, in the subject, when they are administered to the subject.
  • Such salts may include inorganic and organic salts, such as salts of acetic acid, nitric acid, aspartic acid, sulfonic acid, sulfuric acid, maleic acid, glutamic acid, formic acid, succinic acid, phosphoric acid, phthalic acid, tannic acid, tartaric acid, hydrobromic acid, propionic acid, benzene sulfonic acid, benzoic acid, stearic acid, lactic acid, bicarbonic acid, bisulfuric acid, bitartaric acid, oxalic acid, butyric acid, calcium edetate, carbonic acid, chlorobezoic acid, citric acid, edetic acid, toluenesulfonic acid, fumaric acid, gluceptic acid, esilic acid, pamoic acid, gluconic acid, methyl nitric acid, malonic acid, hydrochloric acid, hydroiodic, hydroxynaphtholic acid, isethionic acid
  • the additional salts of base may include salts of akali metal or alkaline earth metal, such as salts of ammonium, lithium, sodium, potassium, magnesium, calcium, and the like; salts having an organic base, such as benzathine, N-methyl-D- glucamine, hydrabamine, and the like; and salts having an amino acid such as arginine, lysine, and the like.
  • these salts may be converted to a released form by treating with a proper base or acid.
  • the compound of Chemical Formula 1 a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or pharmaceutically acceptable salt thereof exhibits an excellent effect on preventing, improving and/or treating epilepsy. Therefore, another embodiment provides a pharmaceutical composition for preventing and/or treating epilepsy containing a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.
  • Another embodiment provides a method of preventing and/or treating epilepsy comprising administering a pharmaceutically effective amount of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of preventing and/or treating epilepsy.
  • the method may further comprise a step of identifying the subject in need of preventing and/or treating epilepsy prior to the step of administering.
  • Another embodiment provides a phenyl carbamate compound represented by Chemical Formula 1 ; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of epilepsy.
  • Another embodiment provides a use of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for preventing and/or treating epilepsy.
  • the epilepsy may include a neurodegeneration (in brain) associated epilepsy. In another concrete embodiment, the epilepsy may not be a muscle spasm associated epilepsy.
  • the pharmaceutical composition may be formulated in various forms for oral or parenteral administration.
  • the pharmaceutical composition may be formulated in the oral administration form, such as a tablet, pill, soft or hard capsule, liquid, suspension, emulsion, syrup, granules, elixirs, and the like.
  • the oral administration form may further include pharmaceutically acceptable and conventional components, for example, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, and the like; a lubricant such as silica, talc, stearic acid, magnesium or calcium salt thereof, polyethyleneglycol, and the like.
  • the oral administration form is a tablet, it may further include a binder such as magnesium aluminium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpirrolidine, and the like; and optionally include one or more additives selected from the group consisting of a disintegrant such as starch, agar, arginic acid or sodium salt thereof, an absorbent, a colorant, a flavoring, a sweetener, and the like.
  • the pharmaceutical composition may also be formulated in a parenteral administration form, which can be administered by subcutaneous injection, intravenous injection, intramuscular injection, injection into thoracic cavity, and the like.
  • the pharmaceutical composition may be prepared as a solution or suspension wherein the active ingredient is dissolved in water together with a stabilizer and/or a buffering agent, and such solution or suspension formulation may be prepared as a dosage form in ample or vial.
  • the pharmaceutical composition may be sterilized, and/or include further additives such as a preservative, a stabilizer, a hydrating agent, an emulsification accelerator, a salt and/or buffering agent for osmoregulation, and the like, and/or further therapeutically effective ingredients.
  • the pharmaceutical composition may be formulated by any conventional method for mixing, granulating, coating, and the like.
  • the pharmaceutical composition may be administered to a mammal including human, in the pharmaceutically effective amount of 0.01 to 750 mg/kg(body weight), preferably 0.1 to 500 mg/kg(body weight) per one day, based on the active ingredient.
  • the pharmaceutically effective amount may refers to an amount capable of exhibiting a desired effect, i,e., an effect of treating and/or preventing epilepsy.
  • the pharmaceutically effective amount may be administered through oral or parenteral pathway (e.g., an intravenous injection, an intramusclular injection, etc.), one or two or more times per one day.
  • the pharmaceutically effective amount and the administration pathway of the present pharmaceutical composition may be properly adjusted by a person skilled in the relevant field considering the conditions of the subject (patient), desired effects, and the like.
  • the subject may be a mammal including human or cells and/or tissues obtained therefrom.
  • the carbamate compound of the present invention may prepared by the following reaction formula.
  • a diol compound used in the synthesis of the carbamate compound may be synthesized by dihydroxylation of a trans-olefin compound.
  • a diol compound having optical activity may be synthesized using a sharpless asymmetric dihydroxylation catalyst.
  • the optically active substance of diol may also be synthesized using a reduction reagent after synthesizing a hydroxy-ketone compound using Haloro-Mandelic acid.
  • PG(protecting group) may be selected from the group consisting of trialkyl silyl group(e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), ester group[Ac(acetate), Bz(benzoate), Pv(pivaloate), Cbz(benzyl carbonate), BOC(t-
  • TMS trimethyl silyl
  • TES
  • PG(protecting group) may be selected from the group consisting of trialkyl silyl group(e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), ester group[Ac(acetate), Bz(benzoate), Pv(pivaloate), Cbz(benzyl carbonate), BOC(t-butyl carbonate), Fmoc(9-fluoroenylmethyl)carbaonate, Alloc(allyl Carbonate), Troc(trichloroethyl carbonate), p-methoxy
  • R4 and R5 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R4 and R5 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
  • Two substances in the form of regioisomers of a single carbamate of diol having halogen substituent at phenyl ring may be separated by flash column chromatography to obtain two kinds of single carbamate compounds.
  • Fig. 1 is a graph showing ED50 values according to time measured through MES.
  • Fig. 2 is a graph showing ED50 values according to time measured through scPTZ.
  • Preparation Example 42 Synthesis of l-(2,6-dichlorophenyl)-(R,R)-l,2-butanediol
  • the substantially same method as described in Preparation Example 15 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-butene(Preparation Example 10) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.96g, yield 60-95%).
  • ⁇ , ⁇ -dimethylhydroxyl amine hydrochloride ( ⁇ , ⁇ -dimethylhydroxylamine.HCl, 15.2g) was dissolved in dichloromethane (DCM, 150ml), and cooled to 0 ° C using an ice-bath. Then, 77.7ml of 2.0M trimethylaluminium in hexane was slowly added thereto in drop-wise manner for 30 minutes. Thereafter, the ice-bath was removed, and the obtained product was stirred at the room temperature for 2 hours.
  • DCM dichloromethane
  • the obtained organic layer was dehydrated with anhydrous magnesium sulfate (MgS0 4 ), filtrated, and concentrated under reduced pressure.
  • the concentrated residue was purified by a silica gel column chromatography to produce the title compound (0.69g, yield 85-95%).
  • the obtained product was diluted with ethylacetate.
  • the obtained organic layer was washed with distilled water, dehydrated with anhydrous magnesium sulfate (MgS0 4 ), filtrated, and concented under reduced pressure.
  • the concentrated residue was purified by a silica gel column chromatography to produce the title compound (7.05g, yield 60-90%).
  • Example 70 The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example70)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (5.7g, yield 60-90%).
  • Example 72 The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(S,R)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example72)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.4g, yield 60 ⁇ 90%).
  • Example73 The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(R,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example73)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
  • Example 7 The substantially same method as described in Example 1 was conducted, except that l-(2- chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation example74)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.6g, yield 60-90%).
  • Example 75 1- (2-chlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 75) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.5g, yield 60-90%).
  • Example 77 1- (2-chlorophenyl)-3-methyl-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 77) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60 ⁇ 90%).
  • Example 78 The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-3-methyl-(R,R)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 78) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.6g, yield 60-90%).
  • Example 79 The substantially same method as described in Example 1 was conducted, except that 1 - (2-chlorophenyl)-3-methyl-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 79) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%).
  • Example 80 1- (2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 80) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
  • Example 81 1- (2-chlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 81) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.2g, yield 60 ⁇ 90%).
  • Example 82 The substantially same method as described in Example 1 was conducted, except that 1 - (2-chlorophenyl)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 82) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.1 g, yield 60-90%).
  • Example 15 The substantially same method as described in Example 15 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-propanediol(Preparation example 15) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (3.36g, yield 60%).
  • Example 15 The substantially same method as described in Example 15 was conducted, except that l-(2-chlorophenyl)-l,2-propanediol(Preparation example 16) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (2.6g, yield 45%).
  • Example 29 The substantially same method as described in Example 29 was conducted, except that propylamine was used instead of methylamine solution(CH 3 NH 2 in EtOH), to obtain the title compound (l .Og, yield 17%).
  • Example 29 The substantially same method as described in Example 29 was conducted, except that isopropylamine was used instead of methylamine solution(CH 3 NH2 in EtOH), to obtain the title compound (0.54g, yield 16%).
  • Example 29 The substantially same method as described in Example 29 was conducted, except that 2-aminonorbornane was used instead of methylamine solution(CH 3 NH2 in EtOH), to obtain the title compound (1.7g, yield 20-50%).
  • Example 83 1- (2,4-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 83) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.8g, yield 60 ⁇ 90%).
  • Example 84 1- (2,6-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane
  • Preparation Example 84 was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.6g, yield 60 ⁇ 90%)
  • Example 85 1- (2,3-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 85) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.4g, yield 60 ⁇ 90%)
  • Example 86 The substantially same method as described in Example 1 was conducted, except that 1 - (2,4-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 86) was used instead of 1 -(2-chlorophenyl)-(S,S)- 1 ,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
  • Example 87 The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 87) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60 ⁇ 90%).
  • Example 88 The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-3-methyl-(S,S)- 1 ,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 88) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane
  • Example 89 The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-3-methyl-(S,S)- 1 ,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 89) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane
  • Example 90 The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-(S,S)-l ,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 90) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.2g, yield 60-90%).
  • Example 91 The substantially same method as described in Example 1 was conducted, except that 1 - (2,6-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 91) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.1 g, yield 60 ⁇ 90%)
  • Example 92 1- (2,4-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 92) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.2g, yield 60-90%),
  • Example 93 1- (2,6-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 93) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%),
  • Example 94 1- (2,3-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 94) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.0g, yield 60-90%)
  • Example 95 1- (2,4-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 95) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
  • Example 97 The substantially same method as described in Example 1 was conducted, except that 1 - (2,4-dichlorophenyl)-3-methyl-(R,R)-l ,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 97) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane
  • Example 2 The substantially same method as described in Example 1 was conducted, except that 1 (2,6-dichlorophenyl)-3-methyl-(R,R)- 1 ,2-(Bis-trimethylsilanyloxy)butane (Preparation Exampl 98) was used instead of l-(2-chlorophenyl)-(S,S)-l ,2-(Bis-trimethylsilanyloxy) propane
  • Example 99 The substantially same method as described in Example 1 was conducted, except that 1 - (2,4-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 99) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.5g, yield 60-90%).
  • Example 100 1- (2,6-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)hexane
  • Preparation Example 100 1- (2,6-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)hexane
  • Preparation Example 70 l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane
  • Example 101 1- (2,4-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 101) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60 ⁇ 90%).
  • Example 102 The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 102) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.4g, yield 60-90%).
  • Example 103 The substantially same method as described in Example 1 was conducted, except that 1- (2,3-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 103) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.6g, yield 60-90%).
  • Example 104 The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 104) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%).
  • Example 105 The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 105) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.4g, yield 60-90%).
  • Example 106 The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-3 -methyl- l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 106) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.9g, yield 60-90%).
  • Example 107 The substantially same method as described in Example 1 was conducted, except that 1 - (2,6-dichlorophenyl)-3 -methyl- l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 107) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%).
  • Example 61 Synthesis of l-(2,4-dichlorophenyl)-l-hydroxyhexyl-2-carbamate(61) The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 108) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.6g, yield 60-90%).
  • Example 109 The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 109) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.5g, yield 60 ⁇ 90%).
  • Example 114 The substantially same method as described in Example 1 was conducted, except that 1- (2-iodophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 114) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.1 g, yield 60-90%).
  • Example 15 The substantially same method as described in Example 68 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-propanediol (Preparation Example 15) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol (Preparation example 14) to obtain the title compound (0.77g, yield 16%).
  • Example 16 The substantially same method as described in Example 68 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-propanediol (Preparation Example 16) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol (Preparation example 14) to obtain the title compound (0.16g, yield 10-30%).
  • Example 71 Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- methylcarb amate(71 )
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 15, to obtain the title compound (0.70g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 22, to obtain the title compound (0.69g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 29, to obtain the title compound (0.73g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 16, to obtain the title compound (0.15g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 23, to obtain the title compound (0.04g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 30, to obtain the title compound (0.15g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 17, to obtain the title compound (0.42g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 24, to obtain the title compound (0.5g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 31, to obtain the title compound (0.09g, yield 10-30%).
  • Example 80 Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- cyclopropylcarbamate(80)
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 18, to obtain the title compound (0.53g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 19, to obtain the title compound (0.24g, yield 10-30%).
  • Example 84 Synthesis of l-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-l- N- cyclohexylcarbamate(84)
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 33, to obtain the title compound (0.26g, yield 10%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 27, to obtain the title compound (0.07g, yield 10-30%).
  • a regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 34, to obtain the title compound (0.2 lg, yield 14%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-propanediol(Preparation example 26)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.05g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-propanediol(Preparation example 38)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.07& yield 24%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,3-dichlorophenyl)-(S,S)-l ,2-propanediol(Preparation example 57)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.08g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-butanediol(Preparation example 29)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.07g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-butanediol(Preparation example 41)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (O.l lg, yield 29%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-(S,S)-l,2-butanediol(Preparation example 32)was used instead of 1 -(2-chlorophenyl)-(S,S)- 1 ,2-propanediol(Preparation example 14), to obtain the title compound (0.01 g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-(S,S)-l,2-butanediol(Preparation example 44)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.03 g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-hexanediol(Preparation example 35)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.2 lg, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-hexanediol(Preparation example 47)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.06g, yield 29%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example 27)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.04g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example 39)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.09g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,3-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example 58)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.25g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-butanediol(Preparation example 30)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4), to obtain the title compound (0.08g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-butanediol(Preparation example 42)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.09g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-(R,R)-l,2-propanediol(Preparation example 33)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4), to obtain the title compound (O.Olg, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-(R,R)-l,2-propanediol(Preparation example 45)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4), to obtain the title compound (O.Olg, yield 10-30%).
  • Example 105 Synthesis of l-(2,4-dichlorophenyl)-(R)-2-hydroxyhexyl-(R)-l- carbamate(105)
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-hexanediol(Preparation example 36)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.2 lg, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-hexanediol(Preparation example 48)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.12g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-l,2-propanediol(Preparation example 28)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.05g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-l,2-propanediol(Preparation example 40)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.06g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,3-dichlorophenyl)-l,2-propanediol(Preparation example 59)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.02g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-l,2-butanediol(Preparation example 31 )was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.07g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-l,2-butanediol(Preparation example 43)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.1 Og, yield 10-30%).
  • Example 112 Synthesis of l-(2,4-dichlorophenyl)-2-hydroxy-3-methyl-butyl-l- carbamate(112)
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-l,2-propanediol(Preparation example 34)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.04g, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-3 -methyl- l,2-propanediol(Preparation example 46)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH), to obtain the title compound (O.Olg, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-l,2-hexanediol(Preparation example 37)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.2 lg, yield 10-30%).
  • Example 68 The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-l,2-hexanediol(Preparation example 49)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.12g, yield 10-30%).
  • mice per dose Three doses of the test sample were administered orally to over 18 mice (6 mice per dose) for evaluating the respective doses at which 50% of the animals are protected from seizure (ED50).
  • ED50 median effective dose
  • the value of ED50 is calculated by Litchfield and Wicoxon log-probit method which is a dose-response relationship.
  • the test results are shown in following Table 3.
  • Experimental animal, male ICR mice and male SD rats were purchased from OrientBio or Nara biotech, Korea, and housed 4-5 mice per a cage for 4-5 days.
  • the range of mice body weight was used between 19 and 26 grams and range of rats body weight was used between 100 and 130 grams.
  • mice ICR or Rat; SD
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice
  • mice mice and male SD rats
  • mice were purchased from OrientBio or Nara biotech, Korea, and housed 4-5 mice per a cage for 4-5 days.
  • the range of mice body weight was used between 19 and 26 grams and range of rats body weight was used between 100 and 130 grams.
  • PTZ(Pentylenetetrazol) was administered subcutaneously in the concentration capable of inducing 97% intermittent convulsions (mice: 100 ⁇ 110mg/kg » bw, ⁇ ⁇ /g, or rats: 90-110 mg/kg « bw, 2 d/g). If clonic seizure was not observed for at least 3 seconds in the PTZ administered animal, it can be considered that the test compound has anti-epilepsy activity.
  • the median effective dose (ED50) is determined using 6 animals per a concentration (total three different concentrations), and calculated by Litchfield and Wicoxon log-probit method which is a dose-response relationship. The obtained results are shown in following Table 3.
  • TD50 means the respective dose of the test compound at which 50% of the test animal exhibit neurotoxicity.
  • mice were pre-trained on the rotarod (Rotarod; Columbus instrument, rota-max, USA) at 6 rpm for 5 min 24 hr prior to the test. The peak time was determined by administration test material's random dose for 0.5, 1, 2, 4 hour. To evaluate the minimal neurotoxicity of the compound, the mice were placed on the Rotarod (rod circle; 3 Cm) at 6rpm and the test animal fails to maintain walking once or more during 1 minute, it can be regarded that the test animal exhibits neurotoxicity. The ratio of TD50 to ED50 (TD50/ED50) is called as a protective index, and useful as a parameter for comparison of pharmaceutical efficacy and neurotoxicity. The obtained results are shown in following Table 3.
  • the obtained results are shown as mean ⁇ sem.
  • the difference between the groups was statistically analyzed by ANOVA, and then, further examined by Dunnett's test or Bonferroni test. If p is less than 0.05, it was determined that the difference between the groups had statistical significance.
  • the ED50 values according to time were measured in the test animals (mice and rats) after oral administration of test compound 1 as described in Biological Experimental Example I. The obtained results are shown in following Table 4 and Fig. 1.
  • test compound 1 exhibits the efficacy duration time of at least 12 hours in both of the tested rats and mice.
  • the ED50 values according to time were measured in the test animals (mice and rats) after intraperitoneal administration of test compound 1 as described in Biological Experimental Example II. The obtained results are shown in following Table 5 and Fig. 2.
  • the test compound 1 exhibits the efficacy duration time of at least 12 hours in both of the tested rats and mice.
  • the administration number of the drug becomes decreased, thereby increasing the administration convenience of a patient.
  • Such advantages may be particularly preferable for a patient suffered from a disease that requires long term administration of a drug, such as epilepsy.
  • the decrease of the administration number may be profitable in economic aspect and helpful to increase the quality of life of the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A phenyl carbamate compound, a pharmaceutical composition for preventing and/or treating epilepsy comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating epilepsy, are provided.

Description

[Title of the Invention]
PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY [Technical Field]
The present invention provides a phenyl carbamate compound, a pharmaceutical composition for preventing and/or treating epilepsy comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating epilepsy.
[Background Art]
Epilepsy is a chronic neurological disorder presenting a wide spectrum of diseases that affects approximately 50 million people worldwide, which corresponds to 1% of the world's burden of disease, equaling breast cancer in women and lung cancer in men. Epilepsy refers to a clinical phenomenon rather than a single disease entity, since there are many forms and causes of epilepsy.
An essential step in the diagnosis and treatment of a patient with a seizure is to determine the type of seizure that has occurred. The main characteristic that distinguishes the different categories of seizure is whether the seizure activity is partial or generalized.
On the basis of clinical and encephalography phenomenon, four subdivisions of epilepsy are recognized: grand mal epilepsy (with subgroups: generalized, focal, jacksonian), petit mal epilepsy, psychomotor or temporal lobe epilepsy (with subgroups: psychomotor proper or tonic with adversive or torsion movements or masticatory phenomenon, automatic with amnesia, or sensory with hallucinations or dream states) and autonomic or diencephalic epilepsy (with flushing, pallor, tachycardia, hypertension, perspiration or other visceral symptoms).
Despite many trials to develop anti-epilepsy drugs, epilepsy is still unmet in efficacies. Therefore, there is a need for improved anti-epilepsy medications.
[Summary of the Invention]
An embodiment provides an organic compound, i.e., phenyl carbamate compound. More particularly, the embodiment is directed to a phenyl carbamate compound of the following Chemical Formula 1 , an enantiomer or a diastereomer thereof, or a mixture of enantiomers or diastereomers; or a pharmaceutically acceptable salt of organic acid or inorganic acid thereof; which has remarkably excellent treatment effect on epilepsy as well as very low toxicity. Also, the compounds of formula I may be useful as a drug especially for the treatment of epilepsy: [Chemical Formula 1]
Figure imgf000003_0001
wherein,
X is a halogen, for example, chlorine, fluorine, iodine, or bromine,
n, that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2,
Rl is a linear or branched alkyl group of C1-C4, for example, methyl group, ethyl group, isopropyl group, or butyl group,
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000003_0002
,
H
B is hydrogen, a carbamoyl derivative represented by ® , trialkyl silyl groups (e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), or a trialkyl silyl ether group, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group,
A and B are not carbamoyl derivatives at same time, and
R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
Another embodiment provides a pharmaceutical composition for of preventing and/or treating epilepsy containing a compound of Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient. Another embodiment provides a method of preventing and/or treating epilepsy comprising administering a pharmaceutically effective amount of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of preventing and/or treating epilepsy.
Another embodiment provides a phenyl carbamate compound represented by Chemical Formula 1 ; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of epilepsy or the manufacture of a pharmaceutical composition for preventing and/or treating epilepsy.
[DETAILED DESCRIPTION OF THE EMBODIMENTS]
Continuing its research work in the field of epilepsy, the present inventors, as results of studies on the development of anti-epilepsy drugs, found that a substituted phenyl carbamate compounds of the following Chemical Formula 1 exhibits remarkably excellent anti-epilepsy activity in various emulation models and simultaneously has very low toxicity, and completed the invention.
Therefore, an embodiment provides an organic compound, i.e., phenyl carbamate derivatives, more particularly, a phenyl carbamate compound represented by following Chemical Formula 1 ; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof:
[Chemical F la 1 ]
Figure imgf000004_0001
Figure imgf000004_0002
wherein,
X is a halogen, for example, chlorine, fluorine, iodine, or bromine,
n, that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2, Rl is a linear or branched alkyl group of C1-C4, for example, methyl group, ethyl group, isopropyl group, or butyl group,
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000004_0003
H
B is hydrogen, a carbamoyl derivative represented by ^ ? trialkyl silyl groups (e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), or a trialkyl silyl ether group, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group,
A and B are not carbamoyl derivatives at same time, and
R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
In a concrete embodiment, the phenyl carbamate compound may be selected from the group consisting of:
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-chlorophenyl)- 1 -hydroxybutyl-2-carbamate,
l-(2-chlorophenyl)-l-hydroxy-3-methyl-butyl-2-carbamate,
1 -(2-chlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-methyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-propylcarbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-isopropyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-cyclopropyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-cyclohexyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-benzyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-bicyclo[2,2, 1 Jheptanecarbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2,6-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate, 1 -(2,6-dichlorophenyl)-l -hydroxybutyl-2-carbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxy-3-methyl-butyl-2-carbamate,
1 -(2,6-dichlorophenyl)- 1 -hydroxy-3 -methyl-butyl-2-carbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2,6-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-methylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-propylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-isopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-cyclopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl-l -N-cyclohexyl carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-benzyl carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
l-(2,4-dichlorophenyl)-2-hydroxy-3-methyl-butyl-l-carbamate,
1 -(2,6-dichlorophenyl)-2 -hydroxy-3 -methyl -butyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2-fiuorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)-l -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxybutyl-2-carbamate,
1 -(2,3-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate, and
1 -(2,3 -dichlorophenyl)-2-hydroxypropyl- 1 -carbamate.
In another concrete embodiment, the compound may not include l-(2-chlorophenyl)-l,2- propanediol, l-(2-chlorophenyl)-l-hydroxybutyl-2-carbamate, and 1 -(2,6-dichlorophenyl)- 1- hydroxybutyl-2-carbamate.
In this compound, 2 chiral carbons exist at positions 1 and 2 from phenyl group substituted with X; thus, the compound may exist in the form of an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers, as well as a racemate.
Alternatively, the compound may be in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt may include an additional salt of acid or base, and its stereochemical isomer. For example, the compound may be in the form of an additional salt of an organic or inorganic acid. The salt may not be specially limited, and include any salts that maintain the activities of their parent compounds, with no undesirable effects, in the subject, when they are administered to the subject. Such salts may include inorganic and organic salts, such as salts of acetic acid, nitric acid, aspartic acid, sulfonic acid, sulfuric acid, maleic acid, glutamic acid, formic acid, succinic acid, phosphoric acid, phthalic acid, tannic acid, tartaric acid, hydrobromic acid, propionic acid, benzene sulfonic acid, benzoic acid, stearic acid, lactic acid, bicarbonic acid, bisulfuric acid, bitartaric acid, oxalic acid, butyric acid, calcium edetate, carbonic acid, chlorobezoic acid, citric acid, edetic acid, toluenesulfonic acid, fumaric acid, gluceptic acid, esilic acid, pamoic acid, gluconic acid, methyl nitric acid, malonic acid, hydrochloric acid, hydroiodic, hydroxynaphtholic acid, isethionic acid, lactobionic acid, mandelic acid, mucic acid, naphthylic acid, muconic acid, p-nitromethanesulfonic acid, hexamic acid, pantothenic acid, monohydrogen phosphoric acid, dihydrogen phosphoric acid, salicylic acid, sulfamic acid, sulfanilic acid, methane sulfonic acid, and the like. The additional salts of base may include salts of akali metal or alkaline earth metal, such as salts of ammonium, lithium, sodium, potassium, magnesium, calcium, and the like; salts having an organic base, such as benzathine, N-methyl-D- glucamine, hydrabamine, and the like; and salts having an amino acid such as arginine, lysine, and the like. In addition, these salts may be converted to a released form by treating with a proper base or acid.
As demonstrated in the following experimental examples, the compound of Chemical Formula 1 ; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or pharmaceutically acceptable salt thereof exhibits an excellent effect on preventing, improving and/or treating epilepsy. Therefore, another embodiment provides a pharmaceutical composition for preventing and/or treating epilepsy containing a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.
Another embodiment provides a method of preventing and/or treating epilepsy comprising administering a pharmaceutically effective amount of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of preventing and/or treating epilepsy. The method may further comprise a step of identifying the subject in need of preventing and/or treating epilepsy prior to the step of administering. Another embodiment provides a phenyl carbamate compound represented by Chemical Formula 1 ; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of epilepsy. Another embodiment provides a use of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for preventing and/or treating epilepsy.
In a concrete embodiment, the epilepsy may include a neurodegeneration (in brain) associated epilepsy. In another concrete embodiment, the epilepsy may not be a muscle spasm associated epilepsy.
The pharmaceutical composition may be formulated in various forms for oral or parenteral administration. For example, the pharmaceutical composition may be formulated in the oral administration form, such as a tablet, pill, soft or hard capsule, liquid, suspension, emulsion, syrup, granules, elixirs, and the like. In addition to the active ingredient, the oral administration form may further include pharmaceutically acceptable and conventional components, for example, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, and the like; a lubricant such as silica, talc, stearic acid, magnesium or calcium salt thereof, polyethyleneglycol, and the like. In the case that the oral administration form is a tablet, it may further include a binder such as magnesium aluminium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpirrolidine, and the like; and optionally include one or more additives selected from the group consisting of a disintegrant such as starch, agar, arginic acid or sodium salt thereof, an absorbent, a colorant, a flavoring, a sweetener, and the like. Alternatively, the pharmaceutical composition may also be formulated in a parenteral administration form, which can be administered by subcutaneous injection, intravenous injection, intramuscular injection, injection into thoracic cavity, and the like. In order to formulate the parenteral administration form, the pharmaceutical composition may be prepared as a solution or suspension wherein the active ingredient is dissolved in water together with a stabilizer and/or a buffering agent, and such solution or suspension formulation may be prepared as a dosage form in ample or vial.
The pharmaceutical composition may be sterilized, and/or include further additives such as a preservative, a stabilizer, a hydrating agent, an emulsification accelerator, a salt and/or buffering agent for osmoregulation, and the like, and/or further therapeutically effective ingredients. The pharmaceutical composition may be formulated by any conventional method for mixing, granulating, coating, and the like.
The pharmaceutical composition may be administered to a mammal including human, in the pharmaceutically effective amount of 0.01 to 750 mg/kg(body weight), preferably 0.1 to 500 mg/kg(body weight) per one day, based on the active ingredient. The pharmaceutically effective amount may refers to an amount capable of exhibiting a desired effect, i,e., an effect of treating and/or preventing epilepsy. The pharmaceutically effective amount may be administered through oral or parenteral pathway (e.g., an intravenous injection, an intramusclular injection, etc.), one or two or more times per one day.
The pharmaceutically effective amount and the administration pathway of the present pharmaceutical composition may be properly adjusted by a person skilled in the relevant field considering the conditions of the subject (patient), desired effects, and the like. The subject may be a mammal including human or cells and/or tissues obtained therefrom.
The carbamate compound of the present invention may prepared by the following reaction formula.
Reaction Formula I: Synthesis of Diol-1
Figure imgf000009_0001
trans olefin Diol
A diol compound used in the synthesis of the carbamate compound may be synthesized by dihydroxylation of a trans-olefin compound. A diol compound having optical activity may be synthesized using a sharpless asymmetric dihydroxylation catalyst.
Reaction Formula II: Synthesis of Diol-2
Figure imgf000009_0002
Haloro- andelic acid
PG = Protecting Group
Figure imgf000009_0003
Protected alcohol υιο'
As indicated in the Reaction Formula II, the optically active substance of diol may also be synthesized using a reduction reagent after synthesizing a hydroxy-ketone compound using Haloro-Mandelic acid. In the Reaction Formula II, PG(protecting group) may be selected from the group consisting of trialkyl silyl group(e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), ester group[Ac(acetate), Bz(benzoate), Pv(pivaloate), Cbz(benzyl carbonate), BOC(t-butyl carbonate), Fmoc(9- fluoroenylmethyl)carbaonate, Alloc(allyl Carbonate), Troc(trichloroethyl carbonate), p- methoxybenzoate, methyl carbonate, and so on] and the like, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group.
Reaction Formula III: Carbamation reaction- 1
Figure imgf000010_0001
As a highly selectivity form of regioisomer of single carbamate of diol having halogen substituent at phenyl ring. (Example 1—14 and 36~67 are synthesized by reaction formula III) Reaction Formula IV: Carbamation reaction-2
Figure imgf000010_0002
Two substances in the form of regioisomers of a single carbamate of diol having halogen substituent at phenyl ring may be separated by flash column chromatography to obtain two kinds of single carbamate compounds. (Example 15~35 and 68-115 are synthesized by reaction formula IV)
Reaction Formula V: Protection reaction
Figure imgf000011_0001
In the Reaction Formula V, PG(protecting group) may be selected from the group consisting of trialkyl silyl group(e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), ester group[Ac(acetate), Bz(benzoate), Pv(pivaloate), Cbz(benzyl carbonate), BOC(t-butyl carbonate), Fmoc(9-fluoroenylmethyl)carbaonate, Alloc(allyl Carbonate), Troc(trichloroethyl carbonate), p-methoxybenzoate, methyl carbonate, and so on] and the like, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group.
In the Reaction Formula IV and V, R4 and R5 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R4 and R5 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
Two substances in the form of regioisomers of a single carbamate of diol having halogen substituent at phenyl ring may be separated by flash column chromatography to obtain two kinds of single carbamate compounds.
[BREIF DESCRIPTION OF DRAWINGS]
Fig. 1 is a graph showing ED50 values according to time measured through MES.
Fig. 2 is a graph showing ED50 values according to time measured through scPTZ.
[EXAMPLE]
The present invention is further explained in more detail with reference to the following examples. These examples, however, should not be interpreted as limiting the scope of the present invention in any manner. Preparation Example 1: Synthesis of l-(2-chlorophenyl)-trans-l-propene
Figure imgf000012_0001
48ml of 2-chlorobenzenaldehyde (0.42mol) and 49.7ml of 3-pentanone (0.47mol) were dissolved in 600mL of hexane in flask, and then stirred with raising the temperature. 53.6ml of Boron trifluoride etherate (BF3OEt2, 0.42mol) was added to the resultant under reflux conditions. When the reaction was completed, water was added thereto. After layer separation, the obtained organic layer was washed twice with IM sodium hydroxide solution (IM NaOH), and then the separated organic layer was washed with water. The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgS04) and concentrated. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (38g, yield 58%). 1H NMR(400MHz, CDC13) 61.94(d, J=4.8Hz, 3H), 6.24(m, 1H), 6.78(d, J=14Hz, lH), 7.11~7.51(m, 4H)
Preparation Example 2: Synthesis of l-(2-chlorophenyl)-trans-l-butene
Figure imgf000012_0002
The substantially same method as described in Preparation Example 1 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (2.9g, yield 83%).
1H NMR(400MHz, CDC13) 51.14(d, J=7.6Hz, 3H), 2.29~2.33(m, 2H), 6.28(dt, J=16Hz, 6.4Hz, 1H), 6.78(d, J= 15.6Hz, 1H), 7.13~7.54(m, 4H)
Preparation Example 3: Synthesis of l-(2-chlorophenyl)-3-methyl-trans-l-butene
Figure imgf000012_0003
The substantially same method as described in Preparation Example 1 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (8.0g, yield 50-90%).
1H NMR(400MHz, CDC13) 51.14(d, J=6.8Hz, 6H), 2.25~2.57(m, 1H), 6.20(dd, J=16Hz, 7.2Hz, 1H), 7.64(d, J=16Hz, 1H), 7.12~7.54(m, 4H)
Preparation Example 4: Synthesis of l-(2-chlorophenyl)-trans-l-hexene
Figure imgf000013_0001
The substantially same method as described in Preparation Example 1 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (lOg, yield 85%).
1H NMR(400MHz, CDC13) 60.96(t, J=7.2Hz, 3H), 1.33~1.56(m, 4H), 2.26~2.32(m, 4H), 6.24(dt, J=15.6Hz, 7Hz, 1H), 6.78(d, J=16Hz, 1H), 7.13~7.54(m, 4H)
Preparation Example 5: Synthesis of l-(2,4-dichlorophenyI)-trans-l-propene
Figure imgf000013_0002
The substantially same method as described in Preparation Example 1 was conducted, except that 2,4-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (2.4g, yield 57%).
1H NMR(400MHz, CDC13) 61.95(dd, J=6.8Hz, 1.6Hz, 3H), 6.24(m, 1H), 6.72(d, J=15.6Hz, 1H), 7.18~7.44(m, 3H)
Preparation Example 6: Synthesis of l-(2,4-dichlorophenyl)-trans-l-butene
Figure imgf000013_0003
The substantially same method as described in Preparation Example 5 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (2.1g, yield 90%).
Ή NMR(400MHz, CDC13) 51.14(d, J=7.6Hz, 3H), 2.20~2.33(m, 2H), 6.26(dt, J=16Hz, 6.8Hz, 1H), 6.70(d, J=l 5.6Hz, 1H), 7.18~7.46(m, 3H) Preparation Example 7: Synthesis of l-(2,6-dichlorophenyI)-3-methyl-trans-l- butene
Figure imgf000014_0001
The substantially same method as described in Preparation Example 5 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (0.23g, yield 10-40%).
1H NMR(400MHz, CDC13) 61.15(d, J=6.8Hz, 6H), 2.53~2.58(m, 1H), 6.19(dd, J=16.4Hz, 6.8Hz, 1H), 6.31(d, J=16.4Hz, 1H), 7.18~7.46(m, 3H)
Preparation Example 8: Synthesis of l-(2,4-dichlorophenyl)-trans-l-hexene
Figure imgf000014_0002
The substantially same method as described in Preparation Example 5 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (3.2g, yield 40-80%).
1H NMR(400MHz, CDC13) 60.96(t, J=7.2Hz, 3H), 1.38-1.52(m, 4H), 2.25-2.3 l(m, 2H),
6.22(dt, J= 15.6Hz, 6.8Hz, 1H), 6.70(d, J=15.6Hz, 1H), 7.18-7.46(m, 3H)
Preparation Example 9: Synthesis of l-(2,6-dichlorophenyl)-trans-l-propene
Figure imgf000014_0003
The substantially same method as described in Preparation Example 1 was conducted, except that 2,6-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.4g, yield 10-40%).
1H NMR(400MHz, CDC13) 51.98(d, J=8Hz, 3H), 6.23~6.31(m, 1H), 6.40(d, J=16Hz, 1H), 7.05~7.32(m, 3H)
Preparation Example 10: Synthesis of l-(2,6-dichlorophenyl)-trans-l-butene
Figure imgf000015_0001
The substantially same method as described in Preparation Example 9 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (1.2g, yield 10-40%).
l NMR(400MHz, CDC13) 51.17(t, J=7.6Hz, 3H), 2.30~2.37(m, 2H), 6.29(dt, J=16.4Hz,
6Hz, 1H), 6.37(d, J=16.4Hz, 1H), 7.05~7.32(m, 3H)
Preparation Example 11: Synthesis of l-(2,6-dichlorophenyl)-3-methyl-trans-l- butene
Figure imgf000015_0002
The substantially same method as described in Preparation Example 9 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (0.23g, yield 10-40%).
1H NMR(400MHz, CDC13) 81.15(d, J=6.8Hz, 6H), 2.53~2.58(m, 1H), 6.19(dd, J=l 6.4Hz, 6.8Hz, 1H), 6.3 l(d, J=16.4Hz, 1H), 7.05~7.32(m, 3H)
Preparation Example 12: Synthesis of l-(2,6-dichlorophenyl)-trans-l-hexene
Figure imgf000015_0003
The substantially same method as described in Preparation Example 9 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (0.2g, yield 10-40%).
Ή NMR(400MHz, CDC13) 50.99(t, J=7.2Hz, 3H),1.14~1.59(m, 4H), 2.30~2.36(m, 2H), 6.24(dt, J=16Hz, 6.6Hz, 1H), 6.38(d, J=16.4Hz, 1H), 7.05~7.33(m, 3H)
Preparation Example 13: Synthesis of l-(2,3-dichlorophenyl)-trans-l-propene
Figure imgf000016_0001
The substantially same method as described in Preparation Example 1 was conducted, except that 2,3-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.2g, yield 10-40%).
1H NMR(400MHz, CDC13) 61.94(d, J=4.8Hz, 3H), 6.24(m, 1H), 6.78(d, J=14Hz, 1H),
7.11~7.51(m, 3H)
Preparation Example 14: Synthesis of l-(2-chlorophenyl)-(S,S)-l,2-propanediol
Figure imgf000016_0002
l-(2-chlorophenyl)-trans-l-propene(1.5g, Preparation Example 1) was dissolved in 30mL of the mixture of t-BuOH H20 (1 :1(V/V)). At 0°C, AD-mix-a (Aldrich, U.S.A.) (13.7g) and methane sulfone amide (CH3S02NH2, 0.76g, 0.0080mol) were added thereto and stirred for overnight. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na2S03) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (1.65g, yield 90%).
1H NMR(400MHz, CDC13) 61.20(d, J=6.4Hz, 3H), 2.48(d, J=4.0Hz 1H), 2.92(d, J=4.4Hz, 1H), 3.93~3.97(m, 1H), 4.97(t, J=4.8Hz, 1H), 7.22~7.51(m, 4H)
13CNMR(100MHz,CDCl3) 518.8, 71.5, 74.4, 127.1, 128.1, 128.9, 129.5, 132.6, 138.9
Preparation Example 15: Synthesis of l-(2-chlorophenyI)-(R,R)-l,2-propanediol
Figure imgf000016_0003
l-(2-chlorophenyl)-trans-l-propene (2.5g, Preparation Example 1) was dissolved in 50mL of the mixture of t-BuOH/H20 (1 :1(V/V)). At 0°C , AD-mix-a (Aldrich, U.S.A.) (23.5g) and methane sulfone amide (CH3S02NH2, l.-27g, 0.013mol) were added thereto and stirred for overnight. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na2S03) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (2.96g, yield 90%).
Ή NMR(400MHz, CDC13) 61.20(d, J=6.4Hz, 3H), 2.48(d, J=4.0Hz, 1H), 2.92(d, J=4.4Hz, 1H), 3.93~3.97(m, 1H), 4.97(t, J=4.8Hz, 1H), 7.22~7.51(m, 4H)
Preparation Example 16: Synthesis of the mixture of l-(2-chlorophenyl)-(S,S)-l,2- propanediol and l-(2-chlorophenyl)-(R,R)-l,2-propanediol
Figure imgf000017_0001
l-(2-chlorophenyl)-trans-l-propene(6.53g, Preparation Example 1) was dissolved in 45 mL of the mixture of acetone/t-BuOH/H20(5:l :l V/V). At the room temperature, N- methylmorpholine-N-oxide (7.5 lg) and Os04 (0.54g) were added thereto and stirred for 2-3 hours. When the reaction was completed, the obtained product was washed with water and methylenechloride (MC). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (6.42g, yield 80%).
Ή NMR(400MHz, CDC13) 61.20(d, J=6.4Hz, 3H), 2.48(d, J=4.0Hz, 1H), 2.92(d,
J=4.4Hz, 1H), 3.93~3.97(m, 1H), 4.97(t, J=4.8Hz, 1H), 7.22~7.51(m, 4H)
Preparation Example 17: Synthesis of l-(2-chlorophenyl)-(S,S)-l,2-butanediol
Figure imgf000017_0002
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2-chlorophenyl)-trans-l-butene(Preparation Example 2) was used instead of l-(2- chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.36g, yield 95%). 1H NMR(400MHz, CDC13) 61.01(t, J=7.4Hz, 3H), 1.52~1.65(m, 2H), 2.01(d, J=4.4Hz, 1H), 2.74(d, J=5.2Hz, 1H), 3.69~3.75(m, 1H), 5.05(t, J=5.0Hz, 1H), 7.23~7.54(m, 4H)
Preparation Example 18: Synthesis of l-(2-chlorophenyl)-(R,R)-l,2-butanediol
Figure imgf000018_0001
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2-chlorophenyl)-trans-l-butene(Preparation Example 2) was used instead of l-(2- chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.84g, yield 60-95%).
1H NMPv(400MHz, CDC13) 61.01(t, J=7.4Hz, 3H), 1.52~1.65(m, 2H), 2.01(d, J=4.4Hz, 1H), 2.74(d, J=5.2Hz, 1H), 3.69~3.75(m, 1H), 5.05(t, J=5.0Hz, 1H), 7.23~7.54(m, 4H)
Preparation Example 19: Synthesis of the mixture of l-(2-chlorophenyl)-(S,S)-l,2- butanediol and l-(2-chlorophenyl)-(R,R)-l,2-butanediol
Figure imgf000018_0002
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2-chlorophenyl)-trans-l-butene(Preparation Example 2) was used instead of l-(2- chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (5.1g, yield 60-90%).
Ή NMR(400MHz, CDC13) 61.01(t, J=7.4Hz, 3H), 1.52~1.65(m, 2H), 2.01(d, J=4.4Hz, 1H), 2.74(d, J=5.2Hz, 1H), 3.69~3.75(m, 1H), 5.05(t, J=5.0Hz, 1H), 7.23~7.54(m, 4H)
Preparation Example 20: Synthesis of l-(2-chlorophenyl)-3-methyl-(S,S)-l,2- butanediol
Figure imgf000018_0003
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2-chlorophenyl)-3 -methyl-trans- l-butene(Preparation Example 3) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.96g, yield 60-90%).
Ή NMR(400MHz, CDC13) 61.07(t, J=7.2Hz, 6H), 1.83~1.89(m, 1H), 1.92(d, J=5.6Hz, 1H), 2.69(d, J=6.4Hz, 1H), 3.53~3.56(m, 1H), 5.22~5.25(m, 1H), 7.23~7.55(m, 4H)
Preparation Example 21: Synthesis of l-(2-chlorophenyl)-3-methyl-(R,R)-l,2- butanediol
Figure imgf000019_0001
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2-chlorophenyl)-3 -methyl-trans- l-butene(Preparation Example 3) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (4.2g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.07(t, J=7.2Hz, 6H), 1.82~1.90(m, 1H), 1.93(d, J=5.6Hz, 1H), 2.79(d, J=6Hz, 1H), 3.53~3.57(m, 1H), 5.23~5.25(m, 1H), 7.23~7.54(m, 4H)
Preparation Example 22: Synthesis of the mixture of l-(2-chlorophenyl)-3-methyl- (S,S)-l,2-butanediol and l-(2-chlorophenyl)-3-methyl-(R,R)-l,2-butanediol
Figure imgf000019_0002
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2-chlorophenyl)-3 -methyl-trans- 1 -butene(Preparation Example 3) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.8g, yield 60-90%).
Ή NMR(400MHz, CDC13) δ1.07(ΐ, J=7.2Hz, 6H), 1.83~1.90(m, 1H), 1.92(d, J=5.6Hz, 1H), 2.69(d, J=6.4Hz, 1H), 3.53~3.56(m, 1H), 5.22~5.25(m, 1H), 7.23~7.55(m, 4H)
Preparation Example 23: Synthesis of l-(2-chlorophenyl)-(S,S)-l,2-hexanediol
Figure imgf000020_0001
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2-chlorophenyl)-trans-l-hexene(Preparation Example 4) was used instead of l-(2- chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.37g, yield 90%).
1H NMR(400MHz, CDC13) 60.90(t, J=7.2Hz, 3H), 1.35~1.65(m, 6H), 2.08(d, J=4.4Hz, 1H), 2.71(d, J=5.2Hz, 1H), 3.78~3.83(m, 1H), 5.04(t, J=5.0Hz, 1H), 7.23~7.53(m, 4H)
Preparation Example 24: Synthesis of l-(2-chlorophenyl)-(R,R)-l,2-hexanediol
Figure imgf000020_0002
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2-chlorophenyl)-trans-l-hexene(Preparation Example 4) was used instead of l-(2- chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (4.2g, yield 60-90%).
1H NMR(400MHz, CDC13) 50.91 (t, J=6.6Hz, 3H), 1.35~1.65(m, 6H), 2.08(d, J=4.8Hz, 1H), 2.70(d, J=5.2Hz, 1H), 3.80~3.83(m, 1H), 5.05(t, J=5.0Hz, 1H), 7.24~7.56(m, 4H)
Preparation Example 25: Synthesis of the mixture of l-(2-chlorophenyl)-(S,S)-l,2- hexanediol and l-(2-chlorophenyl)-(R,R)-l,2-hexanediol
Figure imgf000020_0003
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2-chlorophenyl)-trans-l-hexene(Preparation Example 4) was used instead of l-(2- chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (7.9g, yield 60-90%).
1H NMR(400MHz, CDC13) 50.90(t, J=7.2Hz, 3H), 1.26-1.55(m, 6H), 2.08(d, J=4.4Hz, 1H), 2.71(d, J=5.6Hz, 1H), 3.78~3.84(m, 1H), 5.04(t, J=3.2Hz, 1H), 7.24~7.55(m, 4H) Preparation Example 26: Synthesis of l-(2,4-dichlorophenyl)-(S,S)-l,2-propanediol
Figure imgf000021_0001
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,4-ichlorophenyl)-trans-l-propene(Preparation Example 5) was used instead of 1- (2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.33g, yield 60-95%).
1H NMR(400MHz, CDC13) 61.22(d, J=6.4Hz, 3H), 2.10(d, J=4.4Hz, IH), 2.71(d, J=4.8Hz, IH), 3.90~3.95(m, IH), 4.94(t, J=5.0Hz, IH), 7.31(dd, J=2.0Hz, J=8.0Hz, IH), 7.40(d, J=2.0Hz, IH), 7.49(d, J=8.4Hz, IH)
Preparation Example 27: Synthesis of l-(2,4-dichlorophenyl)-(R,R)-l,2-propanediol
Figure imgf000021_0002
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,4-ichlorophenyl)-trans-l-propene(Preparation Example 5) was used instead of 1- (2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.45g, yield 60-95%).
1H NMR(400MHz, CDC13) 61.22(d, J=6.4Hz, 3H), 2.10(d, J=4.4Hz, IH), 2.71(d, J=4.8Hz, IH), 3.90~3.95(m, IH), 4.94(t, J=5.0Hz, IH), 7.31~7.49(m, 3H)
Preparation Example 28: Synthesis of the mixture of l-(2,4-dichlorophenyl)-(S,S)- 1,2-propanedioI and l-(2,4-dichlorophenyI)-(R,R)-l,2-propanedioI
Figure imgf000021_0003
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,4-ichlorophenyl)-trans-l-propene(Preparation Example 5) was used instead of 1-
(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.45g, yield 60-95%).
1H NMR(400MHz, CDC13) 51.22(d, J=6.4Hz, 3H), 2.10(d, J=4.4Hz, 1H), 2.7 l(d, J=4.8Hz, 1H), 3.90~3.95(m, 1H), 4.94(t, J=5.0Hz, 1H), 7.31~7.49(m, 3H)
Preparation Example 29: Synthesis of l-(2,4-dichlorophenyl)-(S,S)-l,2-butanediol
Figure imgf000022_0001
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,4-dichlorophenyl)-trans-l-butene(Preparation Example 6) was used instead of 1- (2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.32g, yield 90%).
1H NMR(400MHz, CDCI3) 61.02(t, J=7.4Hz, 3H), 1.54-1.61 (m, 2H), 2.07(d, J=4.8Hz, 1H), 2.74(d, J=4.8Hz, 1H), 3.65~3.68(m, 1H), 5.01(t, J=5.0Hz, 1H), 7.31-7.49(m, 3H)
Preparation Example 30: Synthesis of l-(2,4-dichlorophenyl)-(R,R)-l?2-butanediol
Figure imgf000022_0002
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,4-dichlorophenyl)-trans-l-butene(Preparation Example 6) was used instead of 1- (2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.43 g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.02(t, J=7.4Hz, 3H), 1.54~1.61(m, 2H), 2.07(d, J=4.8Hz, 1H), 2.74(d, J=4.8Hz, 1H), 3.65-3.68(m, 1H), 5.01(t, J=5.0Hz, 1H), 7.31~7.49(m, 3H)
Preparation Example 31: Synthesis of the mixture of l-(2,4-dichlorophenyl)-(S,S)- 1,2-butanediol and l-(2,4-dichlorophenyl)-(R,R)-l,2-butanediol
Figure imgf000022_0003
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,4-dichlorophenyl)-trans-l-butene(Preparation Example 6) was used instead of 1- (2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.33g, yield 60-90%).
Ή NMR(400MHz, CDC13) 51.02(t, J=7.4Hz, 3H), 1.54~1.61(m, 2H), 2.07(d, J=4.8Hz, 1H), 2.74(d, J=4.8Hz, 1H), 3.65~3.68(m, 1H), 5.01(t, J=5.0Hz, 1H), 77.31~7.49(m, 3H)
Preparation Example 32: Synthesis of l-(2,4-dichlorophenyl)-3-methyl-(S,S)-l,2- butanediol
Figure imgf000023_0001
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-trans-l-butene(Preparation Example 7) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.25g, yield 60-95%).
1H NMR(400MHz, CDC13) 51.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 2.35(d, J=4.0Hz, 1H), 3.12(d, J=8.4Hz, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 33: Synthesis of l-(2,4-dichlorophenyl)-3-methyl-(R,R)-l,2- butanediol
Figure imgf000023_0002
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,4-dichlorophenyl)-3 -methyl-trans- l-butene(Preparation Example 7) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.36g, yield 60-95%).
Ή NMR(400MHz, CDC13) 61.00(d, J-6.8Hz, 6H), 1.60~1.65(m, 1H), 2.35(d, J=4.0Hz, 1H), 3.12(d, J=8.4Hz, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 34: Synthesis of the mixture of l-(2,4-dichlorophenyl)-3- methyl-(S,S)-l,2-butanediol and l-(2,4-dichlorophenyl)-3-methyl-(R,R)-l,2-butanediol
Figure imgf000024_0001
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-trans-l-butene(Preparation Example 7) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.26g, yield 60-95%).
1H NMR(400MHz, CDC13) 81.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 2.35(d, J=4.0Hz, 1H), 3.12(d, J=8.4Hz, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 35: Synthesis of l-(2,4-dichlorophenyl)-(S,S)-l,2-hexanediol
Figure imgf000024_0002
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,4-dichlorophenyl)-trans-l-hexene(Preparation Example 8) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (l .lg, yield 60-90%).
1H NMR(400MHz, CDC13) 50.89~0.93(m, 3H), 1.30~1.39(m, 2H), 1.49~1.52(m, 2H),
1.56~1.62(m, 2H), 2.05(d, J=5.2Hz, 1H), 2.74(d, J=5.2Hz, 1H), 3.72~3.77(m, 1H), 4.98(t, J=4.8Hz, 1H), 7.28~7.50(m, 3H)
Preparation Example 36: Synthesis of l-(2,4-dichlorophenyl)-(R,R)-l,2-hexanediol
Figure imgf000024_0003
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,4-dichlorophenyl)-trans-l-hexene(Preparation Example 8) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (1.2g, yield 60-95%).
Ή NMR(400MHz, CD.CI3) 50.89~0.93(m, 3H), 1.30~1.39(m, 2H), 1.49~1.52(m, 2H),
1.56~1.62(m, 2H), 2.05(d, J=5.2Hz, 1H), 2.74(d, J=5.2Hz, 1H), 3.72~3.77(m, 1H), 4.98(t, J=4.8Hz, 1H), 7.28~7.50(m, 3H)
Preparation Example 37: Synthesis of the mixture of l-(2,4-dich!orophenyl)-(S,S)- 1,2-hexanediol and l-(2,4-dichlorophenyl)-(R,R)-l,2-hexanediol
Figure imgf000025_0001
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,4-dichlorophenyl)-trans-l-hexene(Preparation Example 8) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.67g, yield 60-95%).
1H NMR(400MHz, CDC13) 50.89~0.93(m, 3H), 1.30~1.39(m, 2H), 1.49~1.52(m, 2H), 1.56~1.62(m, 2H), 2.05(d, J=5.2Hz, 1H), 2.74(d, J=5.2Hz, 1H), 3.72~3.77(m, 1H), 4.98(t, J=4.8Hz, 1H), 7.28~7.50(m, 3H)
Preparation Example 38: Synthesis of l-(2,6-dichlorophenyl)-(S,S)-l,2-propanediol
Figure imgf000025_0002
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-propene(Preparation Example 9) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.9g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.10(d, J=6.4Hz, 3H), 2.72(d, J=2.4Hz, 1H), 3!l0(d, J=8.4Hz, 1H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~7.36(m, 3H)
Preparation Example 39: Synthesis of l-(2,6-dichlorophenyl)-(R,R)-l,2-propanediol
Figure imgf000025_0003
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-propene(Preparation Example 9) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.84g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.10(d, J=6.4Hz, 3H), 2.72(d, J=2.4Hz, 1H), 3.10(d, J=8.4Hz, 1H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~7.36(m, 3H)
Preparation Example 40: Synthesis of the mixture of l-(2,6-dichlorophenyl)-(S,S)- 1,2-propanediol and l-(2,6-dichlorophenyl)-(R,R)-l,2-propanediol
Figure imgf000026_0001
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-propene(Preparation Example 9) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.9 lg, yield 60-90%).
1H NMR(400MHz, CDC13) 51.10(d, J=6.4Hz, 3H), 2.72(d, J=2.4Hz, 1H), 3.10(d, J=8.4Hz, 1H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~7.36(m, 3H)
Preparation Example 41: Synthesis of l-(2,6-dichlorophenyl)-(S,S)-l,2-butanediol
Figure imgf000026_0002
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-butene(Preparation Example 10) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (1.23g, yield 60-95%).
1H NMR(400MHz, CDC13) 50.97(t, J=7.6Hz, 3H), 1.26~1.53(m, 2H), 2.64(dd, J=0.8Hz, J=4.0Hz, 1H), 3.14(d, J=8.4Hz, 1H), 4.22~4.26(m, 1H), 5.26(t, J=8.4Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 42: Synthesis of l-(2,6-dichlorophenyl)-(R,R)-l,2-butanediol
Figure imgf000026_0003
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-butene(Preparation Example 10) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.96g, yield 60-95%).
1H NMR(400MHz, CDC13) 50.97(t, J=7.6Hz, 3H), 1.26~1.53(m, 2H), 2.64(dd, J=0.8Hz, J=4.0Hz, 1H), 3.14(d, J=8.4Hz, 1H), 4.22~4.26(m, 1H), 5.26(t, J=8.4Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 43: Synthesis of the mixture of l-(2,6-dichlorophenyl)-(S,S)- 1,2-butanediol and l-(2,6-dichlorophenyl)-(R,R)-l,2-butanediol
Figure imgf000027_0001
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-butene(Preparation Example 10) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.86g, yield 60-95%).
1H NMR(400MHz, CDC13) 50.97(t, J=7.6Hz, 3H), 1.26~1.53(m, 2H), 2.64(dd, J=0.8Hz, J=4.0Hz, 1H), 3.14(d, J=8.4Hz, 1H), 4.22~4.26(m, 1H), 5.26(t, J=8.4Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 44: Synthesis of l-(2,6-dichlorophenyl)-3-methyl-(S,S)-l,2- butanediol
Figure imgf000027_0002
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,6-dichlorophenyl)-3 -methyl-trans- l-butene(Preparation Example 11) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.25g, yield 60-95%).
1H NMR(400MHz, CDC13) 51.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 2.35(d, J=4.0Hz, 1H), 3.12(d, J=8.4Hz, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17-7.35(m, 3H)
Preparation Example 45: Synthesis of l-(2,6-dichlorophenyl)-3-methyl-(R,R)-l,2- butanediol
Figure imgf000028_0001
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-trans-l-butene(Preparation Example 11) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.37g, yield 60-95%).
1H NMR(400MHz, CDC13) 61.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 2.35(d, J=4.0Hz, 1H), 3.12(d, J=8.4Hz, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 46: Synthesis of the mixture of l-(2,6-dichlorophenyl)-3- methyl- -l,2-butanediol and !-(2,6-dichlorophenyl)-3-methyI-(R,R)-l,2-butanedioI
Figure imgf000028_0002
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,6-dichlorophenyl)-3 -methyl -trans- l-butene(Preparation Example 11) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.47g, yield 60-95%).
1H NMR(400MHz, CDC13) 61.00(d, J=6.8Hz, 6H), 1.60-1.65(m, 1H), 2.35(d, J=4.0Hz, 1H), 3.12(d, J=8.4Hz, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 47: Synthesis of l-(2,6-dichlorophenyl)-(S,S)-l,2-hexanediol
Figure imgf000028_0003
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-hexene(Preparation Example 12) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.36g, yield 60-90%).
1H NMR(400MHz, CDC13) 60.85(t, J=6.8Hz, 3H), 1.20-1.3 l(m, 4H), 1.45-1.53(m, 2H), 2.61~2.62(m, IH), 3.12(d, J=8.4Hz, IH), 4.28~4.33(m, IH), 5.25(t, J=8.4Hz, IH), 7.18~7.35(m, 3H)
Preparation Example 48: Synthesis of l-(2,6-dichlorophenyl)-(R,R)-l,2-hexanediol
Figure imgf000029_0001
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-hexene(Preparation Example 12) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.58g, yield 60-90%).
1H NMR(400MHz, CDC13) 50.85(t, J=6.8Hz, 3H), 1.20-1.3 l(m, 4H), 1.45-1.53(m, 2H), 2.61-2.62(m, IH), 3.12(d, J=8.4Hz, IH), 4.28~4.33(m, IH), 5.25(t, J=8.4Hz, IH), 7.18~7.35(m, 3H)
Preparation Example 49: Synthesis of the mixture of l-(2,6-dichlorophenyl)-(S,S)- 1,2-hexanediol and l-(2,6-dichlorophenyl)-(R,R)-l,2-hexanediol
Figure imgf000029_0002
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,6-dichlorophenyl)-trans-l-hexene(Preparation Example 12) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.62g, yield 60-90%).
Ή NMR(400MHz, CDC13) 50.85(t, J=6.8Hz, 3H), 1.20-1.3 l(m, 4H), 1.45~1.53(m, 2H), 2.61-2.62(m, IH), 3.12(d, J=8.4Hz, IH), 4.28~4.33(m, IH), 5.25(t, J=8.4Hz, IH), 7.18~7.35(m, 3H)
Preparation Example 50: Synthesis of methyl 2-(2-chlorophenyl)-(R)-2- hydroxyacetate
Figure imgf000030_0001
15g of (R)-2-chloromandelic acid was mixed with methanol (CH3OH, 150ml) and phosphorus chloride oxide (POCI3, 0.76ml) in a flask by stirring using a magnetic stirrer at the room temperature for 6 hours. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na2S03) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (15.64g, yield 95%).
1H NMR(400MHz, CDCI3) δ 3.59(d, J=5.2, 1H), 3.79(t, J=6.0, 3H), 5.59(d, J=5.2, 1H), 7.28~7.43(m, 4H)
Preparation Example 51: Synthesis of 2-(2-chlorophenyl)-(R)-2-hydroxy-N- methoxy-N-methylacetamide
Figure imgf000030_0002
Ν,Ο-dimethylhydroxyl amine hydrochloride (Ν,Ο-dimethylhydroxylamine.HCl, 15.2g) was dissolved in dichloromethane (DCM, 150ml), and cooled to 0 °C using an ice-bath. Then, 77.7ml of 2.0M trimethylaluminium in hexane was slowly added thereto in drop-wise manner for 30 minutes. Thereafter, the ice-bath was removed, and the obtained product was stirred at the room temperature for 2 hours. Methyl-2-(2-chlorophenyl)-(R)-2-hydroxyacetate(15.64g) dissolved in dichloromethane(DCM, 150ml) was added in drop-wise manner thereto at the room temperature for 30 minutes, and subjected to reflux for 12 hours. When the reaction was completed, the obtained product was cooled to 0 °C , and washed by a slow drop- wise addition of hydrochloric acid (HC1, 200ml). The obtained organic layer was washed with distilled water and brine, dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (14.68g, yield 82%).
Ή NMR(400MHz, CDC13) 53.23(s, 3H), 3.28(s, 3H), 4.33(d, J=6.0Hz, 1H), 5.81(d, J=5.6Hz, 1H), 7.23~7.42(m, 4H) Preparation Example 52: Synthesis of 2-(2-chlorophenyl)-N-methoxy-(R)-2-(t-butyl dimethlysUoxy)-N-methylacetamide
Figure imgf000031_0001
2-(2-chlorophenyl)-(R)-2-hydroxy-N-methoxy-N-methylacetamide (0.81 g, 3.52mmol) obtained in Preparation Example 51 was dissolved in dichloromethane (DCM), and cooled to 0°C . Imedazole (0.36g, 5.28mmol) was slowly added, and stirred. TBDMS-C1 (t- butyldimethylsily chloride, 0.79g, 5.28mmol) was slowly added. When the reaction was completed, the reaction mixture was quenched with H20. The organic layer was separated and collected. The aqueous layer was extracted with CH2C12 (300mL), dried over MgS0 . Concentration under vacuum provided a title compound.(0.97g, 80-95%).
1H NMR(400MHz, CDC13) 5-0.03(s, 3H), 0.14(s, 3H), 0.94(s, 9H), 2.97(s, 3H), 3.02(s, 3H), 5.83(s, 1H), 7.25~7.60(m, 4H)
Preparation Example 53: Synthesis of l-(2-chlorophenyl)-(R)-l-(t-butyldimethyl- siloxy)prop ane-2-on
Figure imgf000031_0002
2-(2-chlorophenyl)-N-methoxy-(R)-2-(t-butyldimethylsiloxy)-N-methylacetamide(0.9g) obtained in Preparation Example 52 was dissolved in tetrahydrofuran(THF), and cooled to 0 °C . 3.0M methyl magnesium bromide (MeMgBr, 2.18ml) solution in ether was added thereto in drop-wise manner for 30 minutes, and the obtained product was stirred at 0°C . When the reaction was completed, diethylether was added thereto. The obtained product was washed with 10%(w/v) potassium hydrogen sulfate (KHS04> 100ml) and then, washed again with brine. The obtained organic layer was dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concentrated under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (0.69g, yield 85-95%).
Ή NMR(400MHz, CDC13) 5-0.3(s, 3H), 0.14(s, 3H), 0.94(s, 9H), 2.18(s, 3H), 5.50(s, 1H), 7.27~7.56(m, 4H)
Preparation Example 54: Synthesis of l-(2-chlorophenyl)-(R)-l-(t-butyldimethyl- siloxy)-( -2-propanol
Figure imgf000032_0001
l-(2-chlorophenyl)-(R)-l-(t-butyldimethyl-siloxy)propane-2-on(0.14g) obtained in
Preparation Example 53 was dissolved in ether, and cooled to -78 °C . Zinc borohydride(Zn(BH4)2) was slowly added thereto and the obtained product was stirred. When the reaction was completed, the obtained product was washed by H20. The obtained organic layer was washed with H20, dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concentrated under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (0.04g, yield 25-33%, cis : trans = 2 : 1).
1H NMR(400MHz, CDC13) 5-0.11(s, 3H), 0.11(s, 3H), 0.93(S, 9H), 1.07(d, J=6.4 3H), 2.05(d, J=6.4 1H), 4.01~4.05(m, 1H), 5.18(d, J=4.0, 1H), 7.20~7.56(m, 4H)) Preparation Example 55: Synthesis of l-(2-chlorophenyl)-(R,S)-l,2-propanediol
CI OH
1 -(2-chlorophenyl)-(R)- 1 -(t-butyldimethyl-siloxy)-(S)-2-propanol(l 0.38g) obtained in Preparation Example 54 was dissolved in methanol (CH3OH, 100ml), and then, cooled to 0°C . 8M hydrochloric acid(HCl, 56.2ml) was slowly added in drop-wise manner to the obtained product, and then, the obtained product was warmed to the room temperature, and stirred for 15 hours. When the reaction was completed, the obtained product was cooled to 0 °C . 5N sodium hydroxide (NaOH, 30ml) was slowly added thereto, and the obtained product was subjected to vacuum concentration. The obtained product was diluted with ethylacetate. The obtained organic layer was washed with distilled water, dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (7.05g, yield 60-90%).
Ή NMR(400MHz, CDC13) 61.07(d, J=6.8, 3H), 2.01 (d, J=5.6, 1H), 2.6 l(s, 1H), 4.21~4.27(m, 1H), 5.24(d, J=3.6, 1H), 7.22~7.64(m, 4H)
Preparation Example 56: Synthesis of l-(2-chIorophenyI)-(S,R)-l,2-propanedioI
Figure imgf000033_0001
The substantially same method as described in Preparation Example 50-55 was conducted, except that (S)-2-chloromandelic acid was used instead of (R)-2-chloromandelic acid, to obtain the title compound (5.04g, yield 84%).
Ή NMR(400MHz, CDC13) 51.07(d, J=6.8, 3H), 2.00(d, J=5.6, 1H), 2.54(d, J=3.6, 1H), 4.22~4.26(m, 1H), 5.25(t, J=3.2, 1H), 7.22~7.65(m, 4H)
Preparation Example 57: Synthesis of l-(2,3-dichlorophenyl)-(S,S)-l,2-propanediol
Figure imgf000033_0002
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2,3-dichlorophenyl)-trans-l-propene(Preparation Example 13) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.9g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.10(d, J=6.4Hz, 3H), 2.72(d, J=2.4Hz, 1H), 3.10(d, J=8.4Hz, 1H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18- (m, 3H) Preparation Example 58: Synthesis of l-(2,3-dichlorophenyl)-(R,R)-1.2-propanediol
Figure imgf000033_0003
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2,3-dichlorophenyl)-trans-l-propene(Preparation Example 13) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.84g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.10(d, J=6.4Hz, 3H), 2.72(d, J=2.4Hz, 1H), 3.10(d,
J=8.4Hz, 1H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18- (m, 3H) Preparation Example 59: Synthesis of the mixture of l-(2,3-dichlorophenyI)-(S,S)- 1,2-propanediol and l-(2,3-dichlorophenyl)-(R,R)-l,2-propanediol
Figure imgf000034_0001
The substantially same method as described in Preparation Example 16 was conducted, except that l-(2,3-dichlorophenyl)-trans-l-propene(Preparation Example 13) was used instead of l-(2-chlorophenyl)-trans-l-propene(Preparation Example 1), to obtain the title compound (0.91 g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.10(d, J=6.4Hz, 3H), 2.72(d, J=2.4Hz, 1H), 3.10(d, J=8.4Hz, 1H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~(m, 3H)
Preparation Example 60: Synthesis of l-(2-fluorophenyl)-trans-l-propene
Figure imgf000034_0002
The substantially same method as described in Preparation Example 1 was conducted, except that 2-fluorobenzenaldehyde was used instead of 2-chlorobenzenealdehyde, to obtain the title compound (6.67g, yield 61%).
1H NMR(400MHz, CDC13) 61.94(d, J=6.8Hz, 3H), 6.30~6.38(m, 1H), 6.57(d, J=16Hz, 1H), 7.00-7.4 l(m, 4H)
Preparation Example 61: Synthesis of l-(2-fluorophenyl)-(S,S)-l,2-propanediol
Figure imgf000034_0003
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2-fluorophenyl)-trans-l-propene (Preparation Example 60) was used instead of 1- (2-chlorophenyl)-trans-l-propene (Preparation Example 1), to obtain the title compound (6.46g, yield 78%).
]H NMR(400MHz, CDC13) 81.15(d, J=6.4Hz, 3H), 2.43(d, J=3.6Hz, 1H), 2.69(d, J=4.8Hz, 1H), 3.90~3.98(m, 1H), 4.78(dd, J=4.4, 7.2Hz, 1H), 7.04~7.50(m, 4H)
Preparation Example 62: Synthesis of l-(2-fluorophenyI)-(R,R)-l,2-propanediol
Figure imgf000035_0001
The substantially same method as described in Preparation Example 15 was conducted, except that l-(2-fluorophenyl)-trans-l-propene (Preparation Example 60) was used instead of 1- (2-chlorophenyl)-trans-l-propene (Preparation Example 1), to obtain the title compound (3.29g, yield 79%).
1H NMR(400MHz, CDC13) 51.15(d, J=6.4Hz, 3H), 2.43(d, J=3.6Hz, 1H), 2.69(d, J=4.8Hz, 1H), 3.90~3.98(m, 1H), 4.78(dd, J=4.4, 7.2Hz, 1H), 7.04~7.50(m, 4H)
Preparation Example 63: Synthesis of 2-iodobenzenealdehyde
Figure imgf000035_0002
In a flask, 2-iodobenzyl alcohol (4g, 17.09mmol) was dissolved in dichloromethane (MC, 85ml), and then, manganese oxide (Mn02, 14.86g, 170.92mmol) was added thereto. The obtained reaction product was stirred under the reflux condition. When the reaction was completed, the obtained reaction product was cooled to the room temperature, and then, fiteated and concentrated using celite, to obtain the title compound (3.6g, yield 91%).
1H NMR(400MHz, CDCl3)57.30~7.99(m, 4H), 10.10(s, 1H)
Preparation Example 64: Synthesis of l-(2-iodophenyl)-trans-l-propene
Figure imgf000035_0003
The substantially same method as described in Preparation Example 1 was conducted, except that 2-iodobenzenealdehyde (Preparation Example 63) was used instead of 2- chlorobenzenealdehyde, to obtain the title compound (3.4g, yield 65%).
1H NMR(400MHz, CDCl3)61.95(dd, J=6.8Hz, 1.6Hz, 3H), 6.09-6.18(m, 1H), 6.60(dd, J=l 5.66Hz, 1.8Hz, 1H), 6.89~7.84(m, 4H) Preparation Example 65: Synthesis of l-(2-iodophenyl)-trans-l-butene
Figure imgf000036_0001
The substantially same method as described in Preparation Example 64 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (8.5g, yield 75%).
1H NMR(400MHz, CDCl3)51.46(t, J=7.6Hz, 3H), 2.26~2.34(m, 2H), 6.17(dt, J=15.6Hz, 6.6Hz 1H), 6.57(d, J=15.6Hz, 1H), 6.89~7.85(m, 4H)
Preparation Example 66: Synthesis of l-(2-iodophenyl)-(S,S)-l,2-propanediol
Figure imgf000036_0002
The substantially same method as described in Preparation Example 14 was conducted, except that l-(2-iodophenyl)-trans-l-propene (Preparation Example 64) was used instead of 1- (2-chlorophenyl)-trans-l-propene (Preparation Example 1), to obtain the title compound (3.4g, yield 88%).
1H NMR(400MHz, CDCl3)61.27(d, J=6.4Hz, 3H), 2.26(br s, 1H), 2.74(br s, 1H), 3.99(t, J=6.0Hz, 1H), 4.81(d, J=4.0Hz, 1H), 7.01~7.87(m, 4H)
Preparation Example 67: Synthesis of l-(2-iodorophenyl)-(R,R)-l,2-propanediol
Figure imgf000036_0003
The substantially same method as described in Preparation Example 15 was conducted was conducted, except that l-(2-iodophenyl)-trans-l-propene (Preparation Example 64) was used instead of l-(2-chlorophenyl)-trans-l-propene (Preparation Example 1), to obtain the title compound (7.4g, yield 84%).
1H NMR(400MHz, CDCl3)51.26(d, J=6.4Hz, 3H), 2.35(br s, 1H), 2.85(br d, J=4.0Hz, 1H), 3.98(t, J=6.2Hz, 1H), 4.80(dd, J=5.0, 4.4Hz, 1H), 7.00~7.87(m, 4H) Preparation Example 68: Synthesis of l-(2- iodophenyl)-(S,S)-l,2-butanediol
Figure imgf000037_0001
The substantially same method as described in Preparation Example 14 was conducted was conducted, except that l-(2-iodophenyl)-trans-l-butene (Preparation Example 65) was used instead of l-(2-chlorophenyl)-trans-l-propene (Preparation Example 1), to obtain the title compound (9.5g, yield 84%).
1H NMR(400MHz, CDCl3)61.04(t, J=7.6Hz, 3H), 1.60~1.71(m, 2H), 2.07(br s, 1H), 2.74(br s, 1H), 3.71~3.76(m, 1H), 4.87(d, J=4.8Hz, 1H), 7.01~7.87(m, 4H)
Preparation Example 69 : Preparation of l-(2-chlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy) propane
Figure imgf000037_0002
To a stirred solution of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4, 67g, 0.35mol) in CH2C12 (670ml) was added Et3N (200mL, 1.43mol) and TMSC1 (113.9mL, 0.89mol) at 0°C under N2. The reaction mixture was allowed to stir at 0°C for 3hr. The reaction mixture was quenched with H20 (650mL) at 0°C. The organic layer was separated and collected. The aqueous layer was extracted with CH2C12 (300mL), dried over MgS04. Concentration under vacuum provided a crude product. 104.18g (117.44%).
Ή NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.15(d, J=5.6Hz, 3H), 3.977~3.918(m, 1H), 4.973(d, J=6.4Hz, 1H), 7.207-7.165(m,lH), 7.321~7.245(m, 2H), 7.566-7.543 (m, 1H)
Preparation Example 70 : Preparation of l-(2-chlorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy) propane
Figure imgf000037_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-propanediol(Preparation example 15) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (8.5g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.15(d, J=5.6Hz, 3H), 3.977-3.918(m, 1H), 4.973(d, J=6.4Hz, 1H), 7.21~7.54(m,4H)
Preparation Example 71 : Preparation of l-(2-chlorophenyl)--l,2-(Bis- trimethylsilanyloxy) propane
Figure imgf000038_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)propane-l,2-diol(Preparation examplel6)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (5.2g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.15(d, J=5.6Hz, 3H), 3.977-3.918(m, 1H), 4.973(d, J6.4Hz, 1H), 7.21~7.54(m,4H)
Preparation Example 72 : Preparation of l-(2-chlorophenyl)-(S,R)-l,2-(Bis- trimethylsilanyloxy) propane
Figure imgf000038_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-(S,R)-l,2-propanediol(Preparation example56)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14) to obtain the title compound (3.4g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.15(d, J=5.6Hz, 3H), 3.977-3.918(m, 1H), 4.973(d, J=6.4Hz, 1H), 7.21-7.54(m,4H)
Preparation Example 73 : Preparation of l-(2-chIorophenyI)-(R,S)-l,2-(Bis- trimethylsilanyloxy) propane
Figure imgf000039_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-(R,S)-l,2-propanediol(Preparation example55)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.2g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.15(d, J=5.6Hz, 3H), 3.977~3.918(m, 1H), 4.973(d, J=6.4Hz, 1H), 7.21~7.54(m,4H)
Preparation Example 74 : Preparation of l-(2-chlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy) butane
Figure imgf000039_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-(S,S)-l,2-butanediol(Preparation examplel7)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title, compound (3.6g, yield 90-120%).
1H NMR(400MHz, CDCl3)8-0.053(s, 9H), 0.044(s, 9H), 1.01(t, J=7.4Hz, 3H), 1.52~1.65(m, 2H), 3.69~3.75(m, 1H), 5.05(t, J=5.0Hz, 1H), 7.23~7.54(m,4H)
Preparation Example 75 : Preparation of l-(2-chlorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy) butane
Figure imgf000039_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-butanediol(Preparation example 18)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14) to obtain the title compound (3.5g, yield 90-120%).
Ή NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.01(t, J=7.4Hz, 3H), 1.52~1.65(m, 2H), 3.69~3.75(m, 1H), 5.05(t, J=5.0Hz, 1H), 7.23~7.54(m,4H)
Preparation Example 76 : Preparation of l-(2-chlorophenyl)-l,2-(Bis- trimethylsilanyloxy) butane
Figure imgf000040_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-l,2-butanediol(Preparation example 19)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.0g, yield 90-120%).
Ή NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.01(t, J=7.4Hz, 3H), 1.52~1.65(m, 2H), 3.69~3.75(m, 1H), 5.05(t, J=5.0Hz, 1H), 7.23~7.54(m,4H)
Preparation Example 77 : Preparation of l-(2-chIorophenyI)-3-methyI-(S,S)-l,2- (Bis-trimethylsilanyloxy)-butane
Figure imgf000040_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-3-methyl-(S,S)-l,2-butanediol(Preparation example20)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title (2.7g, yield 90-120%).
Ή NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.07(t, J=7.2Hz, 6H), 1.83~1.89(m, 1H), 3.53~3.56(m, 1H), 5.22~5.25(m, 1H), 7.23~7.55(m,4H)
Preparation Example 78 : Preparation of l-(2-chlorophenyl)-3-methyl-(R,R)- l,2-(Bis-trimethylsilanyloxy)-butane
Figure imgf000040_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-3-methyl-(R,R)-l,2-butanediol(Preparation example21)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.4g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.07(t, J=7.2Hz, 6H), 1.83~1.89(m, 1H), 3.53~3.56(m, 1H), 5.22~5.25(m, 1H), 7.23~7.55(m,4H)
Preparation Example 79 : Preparation of l-(2-chlorophenyl)-3-methyl-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000041_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-3 -methyl- l,2-butanediol(Preparation example22)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.8g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.07(t, J=7.2Hz, 6H), 1.83~1.89(m, 1H), 3.53~3.56(m, 1H), 5.22~5.25(m, 1H), 7.23~7.55(m,4H)
Preparation Example 80 : Preparation of l-(2-chlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-hexane
Figure imgf000041_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-(S,S)-l,2-hexanediol(Preparation example23)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.1g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 0.90(t, J=7.2Hz, 3H), 1.35~1.65(m, 6H), 3.78~3.83(m, 1H), 5.04(t, J=5.0Hz, 1H), 7.23~7.53(m,4H)
Preparation Example 81 : Preparation of l-(2-chlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-hexane
Figure imgf000042_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-hexanediol(Preparation example24)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (3.3g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 0.90(t, J=7.2Hz, 3H), 1.35~1.65(m, 6H), 3.78~3.83(m, 1H), 5.04(t, J=5.0Hz, 1H), 7.23~7.53(m,4H)
Preparation Example 82 : Preparation of l-(2-chlorophenyl)-(S,S)-l,2-(Bis- trimethylsiIanyloxy)-hexane
Figure imgf000042_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-chlorophenyl)-l,2-hexanediol(Preparation example25)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (3.2g, yield 90-120%).
Ή NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 0.90(t, J=7.2Hz, 3H), 1.35~1.65(m, 6H), 3.78~3.83(m, 1H), 5.04(t, J=5.0Hz, 1H), 7.23~7.53(m,4H)
Preparation Example 83 : Preparation of l-(2,4-dichlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000042_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-propanediol(Preparation example26)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (2.4g, yield 90-120%).
lH NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.22(d, J=6.4Hz, 3H), 3.90-3.95(m, IH), 4.94(t, J=5.0Hz, IH), 7.31(dd, J=2.0Hz, J=8.0Hz, IH), 7.40(d, J=2.0Hz, IH), 7.49(d, J=8.4Hz, IH)
Preparation Example 84 : Preparation of l-(2,6-dichlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000043_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-propanediol(Preparation example38)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (3.4g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.10(d, J=6.4Hz, 3H), 4.47~4.54(m, IH), 5.24(t, J=8.8Hz, IH), 7.13~7.36(m, 3H)
Preparation Example 85 : Preparation of l-(2,3-dichlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000043_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,3-dichlorophenyl)-(S,S)-l,2-propanediol(Preparation example57)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (2.2g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.10(d, J=6.4Hz, 3H,), 4.47~4.54(m, IH), 5.24(t, J=8.8Hz, IH), 7.18~7.22(m, 3H)
Preparation Example 86 : Preparation of l-(2,4-dichlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000043_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-butanediol(Preparation example29)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.1 g, yield 90- 120%).
Ή NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.02(t, J=7.4Hz, 3H), 1.54~1.61(m, 2H), 3.65~3.68(m, 1H), 5.01(t, J=5.0Hz, 1H), 7.31~7.49(m, 3H)
Preparation Example 87 : Preparation of l-(2,6-dichlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000044_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-butanediol(Preparation example41)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14) to obtain the title compound (2.8g, yield 90-120%).
Ή NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 0.97(t, J=7.6Hz, 3H), 1.26~1.53(m, 2H), 4.22~4.26(m, 1H), 5.26(t, J=8.4Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 88 : Preparation of l-(2,4-dichlorophenyl)-3-methyl-(S,S)- l,2-(Bis-trimethylsilanyloxy)-butane
Figure imgf000044_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-(S,S)-l,2-butanediol(Preparation example32)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (2.7g, yield 90-120%).
Ή NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.30~7.53(m, 3H)
Preparation Example 89 : Preparation of l-(2,6-dichlorophenyl)-3-methyl-(S,S)- l,2-(Bis-trimethylsilanyloxy)-butane
Figure imgf000045_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-(S,S)-l,2-butanediol(Preparation example44)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.3g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 90 : Preparation of l-(2,4-dichlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-hexane
Figure imgf000045_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-hexanediol(Preparation example90)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.6g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 0.89~0.93(m, 3H), 1.30~1.39(m, 2H), 1.49~1.52(m, 2H), 1.56~1.6(m, 2H), 3.72~3.77(m, 1H), 4.98(t, J=4.8Hz, 1H), 7.28~7.50(m, 3H)
Preparation Example 91 : Preparation of l-(2,6-dichlorophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-hexane
Figure imgf000045_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-hexanediol(Preparation example47)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.8g, yield 90-120%).
Ή NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 0.85(t, J=6.7Hz, 3H), 1.20~1.31(m, 4H), 1.45~1.53(m, 2H), 4.28~4.33(m, 1H), 5.25(t, J=8.4Hz, 1H), 7.18~7.35(m, 3H)
Preparation Example 92 : Preparation of l-(2,4-dichlorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000046_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example27)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.2g, yield 90-120%).
Ή NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.22(d, J=6.4Hz, 3H), 3.90~3.95(m, 1H), 4.94(t, J=5.0Hz, 1H), 7.31~7.49(m, 3H)
Preparation Example 93 : Preparation of l-(2,6-dichlorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000046_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example39)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.6g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.10(d, J=6.4Hz, 3H), 4.47-4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~7.36(m, 3H)
Preparation Example 94 : Preparation of l-(2,3-dichlorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyIoxy)-propane
Figure imgf000046_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,3-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example58)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (2.9g, yield 90-120%).
Ή NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.10(d, J=6.4Hz, 3H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~7.22(m, 3H)
Preparation Example 95 : Preparation of l-(2,4-dichlorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000047_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-butanediol(Preparation example30)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propahediol(Preparation exampleH) to obtain the title compound (3.6g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.02(t, J=7.4Hz, 3H), 1.54-1.61 (m, 2H), 3.65~3.68(m, 1H), 5.01(t, J=5.0Hz, 1H), 7.31~7.49(m, 3H)
Preparation Example 96 : Preparation of l-(2,6-dichlorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000047_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-butanediol(Preparation example42)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (3.3g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 0.97(t, J=7.6Hz, 3H), 1.26~1.53(m, 2H), 4.22-4.26(m, 1H), 5.26(t, J=8.4Hz, 1H), 7.17-7.35(m, 3H)
Preparation Example 97 : Preparation of l-(2,4-dichlorophenyl)-3-methyl- (R,R)-l,2-(Bis-trimethylsilanyloxy)-butane
Figure imgf000048_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-(R,R)-l,2-butanediol(Preparation example33)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.5g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.30~7.53(m, 3H)
Preparation Example 98 : Preparation of l-(2,6-dichlorophenyl)-3-methyI- (R,R)-l,2- -trimethylsilanyloxy)-butane
Figure imgf000048_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-(R,R)-l,2-butanediol(Preparation example45)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.4g, yield 90-120%).
1H NMR(400MHz, CDCl3)8-0.053(s, 9H), 0.044(s, 9H), 1.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 99 : Preparation of l-(2,4-dichIorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy)-hexane
Figure imgf000048_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-hexanediol(Preparation example36)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (3.6g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 0.89~0.93(m, 3H), 1.30~1.39(m, 2H), 1.49~1.52(m, 2H), 1.56~1.62(m, 2H), 3.72~3.77(m, 1H), 4.98(t, J=4.8Hz, 1H), 7.28~7.50(m, 3H)
Preparation Example 100 : Preparation of l-(2,6-dichlorophenyl)-(R,R)-l,2- (Bis-trimethylsilanyloxy)-hexane
Figure imgf000049_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-hexanediol(Preparation example48)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.3g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 0.85(t, J=6.7Hz, 3H), 1.20-1.3 l(m, 4H), 1.45~1.53(m, 2H), 4.28~4.33(m, 1H), 5.25(t, J=8.4Hz, 1H), 7.18~7.35(m, 3H)
Preparation Example 101 : Preparation of l-(2,4-dichlorophenyl)-l,2-(Bis- trimethylsiIanyloxy)-propane
Figure imgf000049_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-l,2-propanediol(Preparation example28)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.6g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.22(d, J=6.4Hz, 3H), 3.90~3.95(m, 1H), 4.94(t, J=5.0Hz, 1H), 7.31~7.49(m, 3H)
Preparation Example 102 : Preparation of l-(2,6-dichlorophenyl)-l,2-(Bis- trimethylsilanyloxy)-propane
CI OTMS The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-l,2-propanediol(Preparation example40)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (3.1g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.10(d, J=6.4Hz, 3H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~7.36(m, 3H)
Preparation Example 103 : Preparation of l-(2,3-dichlorophenyl)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000050_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,3-dichlorophenyl)-l,2-propanediol(Preparation example59)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (2.7g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.10(d, J=6.4Hz, 3H), 4.47~4.54(m, 1H), 5.24(t, J=8.8Hz, 1H), 7.18~7.22(m, 3H)
Preparation Example 104 : Preparation of l-(2,4-dichlorophenyl)-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000050_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-l,2-butanediol(Preparation example31)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH) to obtain the title compound (2.9g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.02(t, J=7.4Hz, 3H), 1.54-1.6 l(m, 2H), 3.65~3.68(m, 1H), 5.01(t, J=5.0Hz, 1H), 7.31~7.49(m, 3H)
Preparation Example 105 : Preparation of l-(2,6-dichlorophenyl)-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000051_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-l,2-butanediol(Preparation example43)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleM) to obtain the title compound (3.1g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 0.97(t, J=7.6Hz, 3H), 1.26~1.53(m, 2H), 4.22~4.26(m, 1H), 5.26(t, J=8.4Hz, 1H), 7.17~7.35(m, 3H)
Preparation Example 106 : Preparation of l-(2,4-dichlorophenyl)-3-methyl-l,2- (Bis-trimethylsilanyloxy)-butane
Figure imgf000051_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-l,2-butanediol(Preparation example34)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.7g, yield 90-120%).
Ή NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.00(d, J=6.8Hz, 6H), 1.60~1.65(m, 1H), 4.13~4.18(m, 1H), 5.36(t, J=7.6Hz, 1H), 7.30~7.53(m, 3H)
Preparation Example 107 : Preparation of l-(2,6-dichlorophenyl)-3-methyl-l,2- (Bis-trimethylsilanyloxy)-butane
Figure imgf000051_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-l,2-butanediol(Preparation example46)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleM) to obtain the title compound (2.6g, yield 90-120%). 1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.00(d, J=6.8Hz, 6H), 1.60~1.65(m, IH), 4.13~4.18(m, IH), 5.36(t, J=7.6Hz, IH), 7.17~7.35(m, 3H)
Preparation Example 108 : Preparation of l-(2,4-dichlorophenyl)-l,2-(Bis- trimethylsilanyloxy)-hexane
Figure imgf000052_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,4-dichlorophenyl)-l,2-hexanediol(Preparation example37)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.7g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 0.89-0.93(m, 3H), 1.30~1.39(m, 2H), 1.49~1.52(m, 2H), 1.56~1.62(m, 2H), 3.72~3.77(m, IH), 4.98(t, J=4.8Hz, IH), 7.28~7.50(m, 3H)
Preparation Example 109 : Preparation of l-(2,6-dichlorophenyl)-l,2-(Bis- trimethylsilanyloxy)-hexane
Figure imgf000052_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2,6-dichlorophenyl)-l,2-hexanediol(Preparation example49)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (3.2g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 0.85(t, J=6.7Hz, 3H), 1.20-1.3 l(m, 4H), 1.45~1.53(m, 2H), 4.28~4.33(m, IH), 5.25(t, J=8.4Hz, IH), 7.18~7.35(m, 3H)
Preparation Example 110 : Preparation of l-(2-fluoroophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000053_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-fluoroophenyl)-(S,S)-l,2-propanediol(Preparation example61)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.8g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.15(d, J=6.4Hz, 3H), 3.90~3.98(m, 1H), 4.78(dd, 7=4.4, 7.2Hz, 1H), 7.04~7.50(m, 4H)
Preparation Example 111 : Preparation of l-(2-fulorophenyl)-(R,R)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000053_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-fluoroophenyl)-(R,R)-l,2-propanediol(Preparation example62)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleM) to obtain the title compound (2.5g, yield 90-120%).
1H NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.15(d, J=6.4Hz, 3H), 3.90~3.98(m, 1H), 4.78(dd, J=4.4, 7.2Hz, 1H), 7.04~7.50(m, 4H)
Preparation Example 112 : Preparation of l-(2-iodophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-propane
Figure imgf000053_0003
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-iodophenyl)-(S,S)-l,2-propanediol(Preparation example66)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleM) to obtain the title compound (3.1g, yield 90-120%).
lH NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.27(d, J=6.4Hz, 3H), 3.99(t, J=6.0Hz, 1H), 4.81(d, J=4.0Hz, 1H), 7.01~7.87(m, 4H)
Preparation Example 113 : Preparation of l-(2-iodophenyl)-(R,R)- trimethylsilanyloxy)-prop ane
Figure imgf000054_0001
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-iodophenyl)-(R,R)-l,2-propanediol(Preparation example67)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4) to obtain the title compound (2.8g, yield 90-120%).
1H NMR(400MHz, CDCl3)5-0.053(s, 9H), 0.044(s, 9H), 1.26(d, J=6.4Hz, 3H), 3.98(t, J=6.2Hz, 1H), 4.88(d, J=4.4Hz, 1H), 7.00~7.87(m, 4H)
Preparation Example 114 : Preparation of l-(2-iodophenyl)-(S,S)-l,2-(Bis- trimethylsilanyloxy)-butane
Figure imgf000054_0002
The substantially same method as described in Preparation Example 69 was conducted, except that l-(2-iodophenyl)-(S,S)-l,2-butanediol(Preparation example68)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14) to obtain the title compound (3.3g, yield 90-120%).
Ή NMR(400MHz, CDCl3)6-0.053(s, 9H), 0.044(s, 9H), 1.04(t, J=7.6Hz, 3H), 1.60~1.71(m, 2H), 3.71~3.76(m, 1H), 4.87(d, J=4.8Hz, 1H), 7.01~7.87(m, 4H)
Example 1 : Preparation of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(S)-2- carbamate(l)
Figure imgf000054_0003
To a stirred solution of crude l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane(preparation example69, 104g, 0.31mol) in toluene (670mL) was added by Chlorosulfonyl isocynate(62.5mL, 0.71mol) at 0°C. The reaction mixture was stirred for 2hr.
The reaction mixture was quenched with ice water and then was stirred by additional cold H20 (500mL) for 2hr. After separation of organic layer, the aqueous was adjusted pH2~3 with sat. NaHCO3(400mL) and extracted with EtOAc (300mL x3). The EtOAc layer was washed with sat. NaHC03 (500mL) and H2O(500mL). The organic phase was treated with Charcol for 1.5hr. The organic phase was filtered with Cellite, dreid over MgS04. Filterion and concentration under vacuum provided the title compound of white solid(yield 85%(71.1g), ee = 99.9% MP =
83~84°C, [a]D=+57.8(c=0.25, MeOH))
1H NMR(400MHz, CDC13) 51.24(d, J=6.4, 3H), 2.91(d, J=4.8, 1H), 4.68(br s, 2H), 5.06~5.09(m, 1H), 5.18~5.21(m, 1H), 7.23~7.39(m, 3H), 7.55(dd, J=1.6, J=7.8, 1H)
13C NMR(100MHz, CDC13) 516.4, 73.1, 75.0, 127.0, 128.4, 129.1, 129.5, 132.7, 138.0, 156.6
Example 2 : Preparation of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(R)-2- carbamate(2)
Figure imgf000055_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example70)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (5.7g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.24(d, J=6.4, 3H), 2.91(d, J=4.8, 1H), 4.68(br s, 2H), 5.06~5.09(m, 1H), 5.18~5.21(m, 1H), 7.23~7.39(m, 3H), 7.55(dd, J=1.6, J=7.8, 1H)
Example 3 : Preparation of l-(2-chlorophenyl)-l-hydroxypropyl-2-carbamate(3)
Figure imgf000055_0002
The substantially same method as described in Example 1 was conducted, except that 1-
(2-chlorophenyl)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example71)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethyIsilanyloxy) propane (Preparation example69) to obtain the title compound (3.8g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.24(d, J=6.4, 3H), 2.91(d, J=4.8, 1H), 4.68(br s, 2H), 5.06~5.09(m, 1H), 5.18~5.21(m, 1H), 7.23~7.39(m, 3H), 7.55(dd, J=1.6, J=7.8, 1H)
Example 4 : Preparation of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(R)-2- carbamate(4)
Figure imgf000056_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(S,R)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example72)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.4g, yield 60~90%).
1H NMR(400MHz, CDC13) 61.24(d, J=6.4, 3H), 2.91(d, J=4.8, 1H), 4.68(br s, 2H), 5.06~5.09(m, 1H), 5.18~5.21(m, 1H), 7.23~7.39(m, 3H), 7.55(dd, J=1.6, J=7.8, 1H)
Example 5 : Preparation of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(S)-2- carbamate(5)
Figure imgf000056_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(R,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example73)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.24(d, J=6.4, 3H), 2.91(d, J=4.8, 1H), 4.68(br s, 2H), 5.06~5.09(m, 1H), 5.18~5.21(m, 1H), 7.23~7.39(m, 3H), 7.55(dd, J=1.6, J=7.8, 1H)
Example 6 : Preparation of l-(2-chlorophenyl)-(S)-l-hydroxybutyl-(S)-2- carbamate(6)
Figure imgf000057_0001
The substantially same method as described in Example 1 was conducted, except that l-(2- chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation example74)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.6g, yield 60-90%).
1H NMR(400MHz, CDC13) 60.96(t, J= 7.4Hz, 3H), 1.57~1.73(m, 2H), 3.01(d, J= 5.6Hz, 1H), 4.74(br s, 2H), 4.95(dt, J= 7.2, 8.8Hz, 1H), 5.23(t, J= 5.6Hz, 1H), 7.22~7.54(m, 4H)
Example 7: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxybtyl-(R)-2- carbamate(7)
Figure imgf000057_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 75) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.5g, yield 60-90%).
1H NMR(400MHz, CDC13) δ 0.94(t, J=7.4Hz, 3H), 1.53~1.73(m, 2H), 2.92(s, 1H), 4.78(br s, 2H), 4.91~4.96(m, 1H), 5.22(d, J=5.5Hz, 1H), 7.20~7.54(m, 4H)
Example 8: Synthesis of l-(2-chlorophenyl)-l-hydroxybutyl-2-carbamate(8)
Figure imgf000057_0003
The substantially same method as described in Example 1 was conducted, except that 1-
(2-chlorophenyl)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 76) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.9g, yield 60-90%). 1H NMR(400MHz, CDC13) δ 0.97(t, J=7Hz, 3H), 1.58~1.74(m, 2H), 2.94(d, J=6Hz, 1H), 4.69(br s, 2H), 4.94~4.99(m, 1H), 5.24(t, J=6Hz, 1H), 7.23~7.56(m, 4H)
Example 9: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxy-3-methyl-butyl-(S)-2- carbamate(9)
Figure imgf000058_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-3-methyl-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 77) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60~90%).
Ή NMR(400MHz, CDC13) 61.01(d, J = 6.4Hz, 3H), 1.09(d, J= 6.8Hz, 3H), 2.06(m, 1H), 2.75(d, J= 6.8Hz, 1H), 4.58(br s, 2H), 4.85~4.88(m, 1H), 5.34~5.37(m, 1H), 7.22~7.33(m, 2H), 7.35~7.37(m, 1H), 7.51~7.53(m, 1H)
Example 10: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxy-3-methyl-butyl-(R)-2- carbamate(lO)
Figure imgf000058_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-3-methyl-(R,R)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 78) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.6g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.01(d, J= 6.8Hz, 3H), 1.09(d, J= 6.8Hz, 3H), 2.06(m, 1H), 2.73(d, J= 6.8Hz, 1H), 4.57(br s, 2H), 4.85~4.88(m, 1H), 5.34~5.37(m, 1H), 7.24~7.30(m, 2H), 7.35~7.37(m, 1H), 7.51~7.53(m, 1H)
Example 11: Synthesis of l-(2-chlorophenyl)-l-hydroxy-3-methyl-butyl-2- carbamate(U)
Figure imgf000059_0001
The substantially same method as described in Example 1 was conducted, except that 1 - (2-chlorophenyl)-3-methyl-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 79) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.00(d, J=6.4Hz, 3H), 1.09(d, J=6.4Hz, 3H), 2.08(m, 1H), 2.76(d, J=6.0Hz, 1H), 4.59(br s, 2H), 4.87(dd, J=7.2Hz, 4.4Hz, 1H), 5.36(t, J=4.6, 1H), 7.23~7.54(m, 4H)
Example 12: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxyhexyl-(S)-2- carbamate(12)
Figure imgf000059_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 80) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
1H NMR(400MHz, CDC13) 60.88(t, J= 7Hz, 3H), 1.33~1.42(m, 4H), 1.53~1.71(m, 2H), 2.89(d, J= 5.6Hz, 1H) 4.64(br s, 2H), 5.04(dt, J= 5.0, 9.0Hz, 1H), 5.20(t, J= 5.6Hz, 1H), 7.23~7.55(m, 4H)
Example 13: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxyhexyl-(R)-2- carbamate(13)
Figure imgf000059_0003
The substantially same method as described in Example 1 was conducted, except that 1- (2-chlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 81) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.2g, yield 60~90%).
1H NMR(400MHz, CDCI3) δ 0.89(dd, J=5Hz, 3H), 1.28~1.43(m, 4H), 1.52~1.58(m, IH), 1.65~1.72(m, IH), 2.90(d, J=6Hz, IH), 4.64(br s, 2H), 5.01~5.06(m, IH), 5.22(t, J=6Hz, IH), 7.22~7.56(m, 4H)
Example 14: Synthesis of l-(2-chIorophenyl)-l-hydroxyhexyl-2-carbamate(14)
Figure imgf000060_0001
The substantially same method as described in Example 1 was conducted, except that 1 - (2-chlorophenyl)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 82) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.1 g, yield 60-90%).
1H NMR(400MHz, CDC13) δ 0.88(dd, J=5Hz, 3H), 1.31~1.43(m, 4H), 1.63~1.70(m, IH), 1.52~1.60(m, IH), 3.06(d, J=6Hz, IH), 4.75(br s, 2H), 5.00~5.05(m, IH), 5.21(t, J=6Hz, IH), 7.22~7.55(m, 4H)
Example 15: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(S)-2-N- methylcarbamate(15)
CI OH
O
l-(2-chlorophenyl)-(S,S)-l,2-propanediol(2.4g) obtained in Preparation Example 14, tetrahydrofuran (THF, 12ml), and carbonyldiimidazole (CDI, 3.12g) were put into a flask and stirred at the room temperature. After approximately 3 hours, methylamine solution(CH3NH2, 4ml(33% in EtOH)) was added thereto. When the reaction was completed, the obtained product was washed with 1M HC1 solution and ethylacetate (EA). The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography, to obtain the title compound (1.6g, yield 51%).
1H NMR(400MHz, CDC13) 61.03~1.25(m, 3H), 2.76(s, 3H), 3.34(s, 1H), 4.80(br s 1H), 5.04(t, J=12.5Hz, 1H), 5.14(s, 1H), 7.20~7.53(m, 4H)
Example 16: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(S)-2-N- propylcarbamate(16)
Figure imgf000061_0001
The substantially same method as described in Example 15 was conducted, except that propylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (0.79g, yield 25%).
1H NMR(400MHz, CDC13) 60.90(t, J=6.8Hz, 3H), 1.20(d, J=5.96Hz, 3H), 1.49(dd, J=14.2Hz, 2H), 3.11(d, J=6.28Hz, 2H), 3.34(s, 1H), 4.84(br s, 1H), 5.05(t, J=5.88Hz, 1H), 5.14(s, 1H), 7.22~7.53(m, 4H)
Example 17: Synthesis of l-(2-chlorophenyI)-(S)-l-hydroxypropyl-(R)-2-N- isopropylcarbamate(17)
Figure imgf000061_0002
The substantially same method as described in Example 15 was conducted, except that isopropylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (1.5g, yield 41%).
1H NMR(400MHz, CDC13) 61.14(dd, J=6.5Hz, 6H), 1.19(d, J=6.4Hz, 3H), 3.21(s, 1H), 3.73~3.82(m, 1H), 4.59(br s, 1H), 5.01~5.07(m, 1H), 5.14(t, J=5.8Hz, 1H), 7.20~7.53(m, 4H)
Example 18: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(R)-2-N- cy clopropylcarb amate(l 8)
Figure imgf000062_0001
The substantially same method as described in Example 15 was conducted, except that cyclopropylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (2.2g, yield 43%).
1H NMR(400MHz, CDC13) 50.50~0.56(m, 2H), 0.74(d, J=7.21Hz, 2H), 1.25(s, 3H), 2.56~2.61(m, 1H), 3.72(s, 1H), 4.98(br s, 1H), 5.05~5.11(m, 1H), 7.16(s, 1H), 7.23~7.54(m, 4H)
Example 19: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(R)-2-N- cyclohexyl carbamate(19)
Figure imgf000062_0002
The substantially same method as described in Example 15 was conducted, except that cyclohexylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (1.1 g, yield 26%).
Ή NMR(400MHz, CDC13) 61.06~1.40(m, 7H), 1.56~1.61(m, 2H), 1.69~1.71(m, 2H), 1.87~1.94(m, 2H), 3.19(d, J=4.32Hz, 1H), 3.45(s, 1H), 4.64(br s 1H), 5.02~5.07(m, 1H), 5.14(t, J=6.08Hz, 1H) 7.20~7.53(m, 4H)
Example 20: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(S)-2-N-benzyl carbamate(20)
Figure imgf000062_0003
The substantially same method as described in Example 15 was conducted, except that benzylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (1.2g, yield 18%).
1H NMR(400MHz, CDC13) δ 1.27(d, J=10Hz, 3H), 3.12(d, J=5Hz, 1H), 4.37(d, J=6Hz, 2H), 5.12~5.19(m, 3H), 7.15~7.56(m, 9H)
Example 21: Synthesis of l-(2-chlorophenyl)-(S)-l-hydroxypropyl-(S)-2- N- bicyclo [2,2, 1 ] heptanescarbama te(21 )
Figure imgf000063_0001
The substantially same method as described in Example 15 was conducted, except that 2-aminonorbornane was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (1.7g, yield 32%).
1H NMR(400MHz, CDC13) 61.08~1.35(m, 9H), 1.65(br s, 1H), 1.75~1.71(m, 1H), 2.14~2.24(m, 1H), 2.27~2.30(m, 1H), 3.23~3.29(m, 1H), 3.47~3.52(m, 1H), 4.67(br s, 1H), 5.01~5.09(m, 1H), 5.12~5.18(m, 1H), 7.22~7.55(m, 4H)
Example 22: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(R)-2- N- methylcarbamate 22)
Figure imgf000063_0002
The substantially same method as described in Example 15 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-propanediol(Preparation example 15) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (3.36g, yield 60%).
lH NMR(400MHz, CDC13) δ 1.20(d, J=6.8Hz, 3H), 2.80(d, J=4.8Hz, 3H), 3.20(d, J=4.4Hz, 1H), 4.75(br s, 1H), 5.03~5.09(m, 1H), 5.14~5.17(m, 1H), 7.22~7.55(m, 4H)
Example 23: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(R)-2- N- ' propylcarbamate(23)
Figure imgf000064_0001
The substantially same method as described in Example 22 was conducted, except that propylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (3.1g, yield 53%).
1H NMR(400MHz, CDC13) 60.92(t, J=7.6Hz, 3H), 1.21(d, J=6.4Hz, 3H), 1.51(m, 2H), 3.09-3.14(m, 2H), 3.28(d, J=4.4Hz, 1H), 4.82(br s, 1H), 5.03~5.09(m, 1H), 5.14~5.17(m, 1H), 7.22~7.55(m. 4H)
Example 24: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxypropyI-(R)-2- N- isoprop lcarbamate(24)
Figure imgf000064_0002
The substantially same method as described in Example 22 was conducted, except that isopropylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (0.16g, yield 27%).
Ή NMR(400MHz, CDC13) 50.88~1.16(m, 6H), 1.19~1.26(m, 3H), 3.34(s, 1H), 3.71~3.78(m, 1H), 4.62(br s, 1H), 5.03(t, J=5.8Hz, 1H), 5.13(d, J=4.9Hz, 1H), 7.20~7.53(m, 4H)
Example 25: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(R)-2- N- cyclopropylcarbamate(25)
Figure imgf000064_0003
The substantially same method as described in Example 22 was conducted, except that cyclopropylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (3.7g, yield 60%).
1H NMR(400MHz, CDC13) 50.49~0.54(m, 2H), 0.74(d, J=7.2Hz, 2H), 1.22(s, 3H), 2.55~2.60(m, 1H), 3.16(s, 1H), 5.00(s, 1H), 5.04~5.11(m, 1H), 5.16(s, 1H), 7.23~7.54(m, 4H)
Example 26: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(R)-2- N- cyclohexyl carbamate(26)
Figure imgf000065_0001
The substantially same method as described in Example 22 was conducted, except that cyclohexylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (1.9g, yield 28%).
1H NMR(400MHz, CDC13) 51.05~1.38(m, 8H), 1.58~1.70(m, 3H), 1.85~1.95(m, 2H), 3.39~3.47(m, 1H), 3.56(s, 1H), 4.79(br s, 1H), 5.01~5.07(m, 1H), 5.14(t, J=5.2Hz, 1H), 7.20~7.54(m, 4H)
Example 27: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(R)-2- N- benzylcarbamate(27)
Figure imgf000065_0002
The substantially same method as described in Example 22 was conducted, except that benzylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (0.52g, yield 19%).
1H NMR(400MHz, CDC13) 61.25(d, J=6Hz, 3H), 1.64(s, 1H), 3.13(d, J=4.4Hz, 1H), 4.37(d, J=5.6Hz, 2H), 5.12~5.19(m, 2H), 7.23~7.55(m, 9H)
Example 28: Synthesis of l-(2-chlorophenyl)-(R)-l-hydroxypropyl-(R)-2- N- bicyclo[2,2,l]heptanecarbamate(28)
Figure imgf000065_0003
The substantially same method as described in Example 22 was conducted, except that 2-aminonorbornane was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (1.7g, yield 20-50%).
1H NMR(400MHz, CDC13) 61.08~1.35(m, 9H), 1.65(br s, IH), 1.75~1.71(m, IH), 2.14~2.24(m, IH), 2.27~2.30(m, IH), 3.23~3.29(m, IH), 3.47~3.52(m, IH), 4.67(br s, IH), 5.01~5.09(m, IH), 5.12~5.18(m, IH), 7.22~7.55(m, 4H)
Example 29: Synthesis of l-(2-chlorophenyl)-l-hydroxypropyl-2- N- methylcarbamate(29)
Figure imgf000066_0001
The substantially same method as described in Example 15 was conducted, except that l-(2-chlorophenyl)-l,2-propanediol(Preparation example 16) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (2.6g, yield 45%).
1H NMR(400MHz, CDC13) δ 1.21(d, J=6Hz, 3H), 2.81(d, J=5Hz, 3H), 3.14(d, J=4Hz, IH), 4.72(br s, IH), 5.07(dd, J=6Hz, IH), 5.16(t, J=6Hz, IH), 7.22~7.56(m, 4H)
Example 30: Synthesis of l-(2-chlorophenyl)-l-hydroxypropyl-2- N- propylcarbamate(30)
Figure imgf000066_0002
The substantially same method as described in Example 29 was conducted, except that propylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (l .Og, yield 17%).
1H NMR(400MHz, CDC13) δ 0.92(t, J=7Hz, 3H), 1.21(d, J=6Hz, 3H), 1.53(dd, J=7Hz, 2H), 3.13(dd, J=7Hz, 2H), 3.28(d, IH), 4.82(S, IH), 5.06(dd, J=7Hz, IH), 5.16(t, J=5Hz, IH), 7.21~7.56(m, 4H) Example 31: Synthesis of l-(2-chlorophenyl)-l-hydroxypropyl-2- N- isopropylcarbamate(31)
Figure imgf000067_0001
The substantially same method as described in Example 29 was conducted, except that isopropylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (0.54g, yield 16%).
1H NM (400MHz, CDC13) δ 1.16(dd, J=6Hz, 6H), 1.21(d, J=6Hz, 3H), 3.23(d, J=6Hz, 1H), 3.75~3.84(m, 1H), 4.61(br s, 1H), 5.06(t, J=6Hz, 1H), 5.16(t, J=6Hz, 1H), 7.22~7.56(m, 4H)
Example 32: Synthesis of l-(2-chlorophenyl)-l-hydroxypropyl-2- N- cyclopropylcarbamate(32)
Figure imgf000067_0002
The substantially same method as described in Example 29 was conducted, except that cyclopropylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (l .Og, yield 17%).
1H NMR(400MHz, CDC13) δ 0.50(t, J=6Hz, 2H), 0.77(t, J=3Hz, 2H), 1.12(d, J=7Hz, 3H), 2.53~2.59(m, 1H), 3.22(d, J=4Hz, 1H), 5.08(dd, J=6Hz, 1H), 5.15(S, 1H), 7.22~7.55(m, 4H)
Example 33: Synthesis of l-(2-chlorophenyI)-l-hydroxypropyl-2- N- cyclohexylcarbamate(33)
Figure imgf000067_0003
The substantially same method as described in Example 29 was conducted, except that cyclohexylamine was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (2.2g, yield 33%).
1H NMR(400MHz, CDC13) 6 1.07-1.17(m, 3H), 1.21(d, J=6Hz, 3H), 1.29~1.42(m, 3H), 1.72(dd, J=6Hz, 2H), 1.92(dd, J=6Hz, 2H), 3.26(d, J=4Hz, IH), 3.46(t, J=4Hz, IH), 4.68(d, J=6Hz, IH), 5.07(dd, J=6Hz, IH), 5.16(t, J=6Hz, IH), 7.22~7.55(m, 4H)
Example 34: Synthesis of l-(2-chlorophenyl)-l-hydroxypropyl-2- N- benzylcarbamate(34)
Figure imgf000068_0001
The substantially same method as described in Example 29 was conducted, except that benzylamine was used instead of methylamine solution(CH3N¾ in EtOH), to obtain the title compound (1.3g, yield 19%).
]H NMR(400MHz, CDC13) δ 1.25(d, J=6Hz, 3H), 3.16(d, J=4Hz, IH), 4.36(d, J=6Hz, 2H), 5.14(dd, J=6Hz, 3H), 7.23~7.56(m, 9H), yield:19%(1.3g)
Example 35: Synthesis of l-(2-chlorophenyl)-l-hydroxypropyl-2- N- bicyclo[2,2,l]heptanecarbamate(35)
Figure imgf000068_0002
The substantially same method as described in Example 29 was conducted, except that 2-aminonorbornane was used instead of methylamine solution(CH3NH2 in EtOH), to obtain the title compound (1.7g, yield 20-50%).
1H NMR(400MHz, CDC13) 61.08~1.35(m, 9H), 1.65(br s, IH), 1.75~1.71(m, IH), 2.14~2.24(m, IH), 2.27~2.30(m, IH), 3.23~3.29(m, IH), 3.47~3.52(m, IH), 4.67(br s, IH), 5.01~5.09(m, IH), 5.12-5.18(m, IH), 7.22~7.55(m, 4H)
Example 36: Synthesis of l-(2,4-dichlorophenyl)-(S)-l-hydroxypropyl-(S)-2- carbamate(36)
Figure imgf000069_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 83) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.8g, yield 60~90%).
Ή NMR(400MHz, CDC13) 61.22(d, J= 6.4Hz, 3H), 4.16(br t, 1H) 4.96(br t, 3H), 5.07(t, J = 4.8Hz, 1H), 7.23~7.52(m, 3H)
Example 37: Synthesis of l-(2,6-dichlorophenyl)-(S)-l-hydroxypropyl-(S)-2- carbamate(37)
Figure imgf000069_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 84) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.6g, yield 60~90%)
Example 38 : Synthesis of l-(2,3-dichlorophenyl)-(S)-l-hydroxypropyl-(S)-2- carbamate(38)
Figure imgf000069_0003
The substantially same method as described in Example 1 was conducted, except that 1- (2,3-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 85) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.4g, yield 60~90%)
Ή NMR(400MHz, CDC13) 6l.l5(d, J= 6.4Hz, 3H), 3.66(d, J= 9.2Hz, 1H), 4.73(br s,
2H), 5.43(t, J= 9.0Hz, 1H), 5.62~5.69(m, 1H), 7.18~7.22(m, 3H), Example 39: Synthesis of l-(2,4-dichlorophenyl)-(S)-l-hydroxybutyl-(S)-2- carbamate(39)
Figure imgf000070_0001
The substantially same method as described in Example 1 was conducted, except that 1 - (2,4-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 86) was used instead of 1 -(2-chlorophenyl)-(S,S)- 1 ,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
Ή NMR(400MHz, CDC13) 60.96(t, J= 7.4Hz, 3H), 1.58~1.74(m, 2H), 2.98(d, J =
5.6Hz, 1H) 4.68(br s, 2H), 5.59(dt, J= 5.2, 8.8Hz, 1H), 5.19(t, J= 5.4Hz, 1H), 7.30~7.50(m, 3H)
Example 40: Synthesis of l-(2,6-dichlorophenyl)-(S)-l-hydroxybutyl-(S)-2- carbamate(40)
Figure imgf000070_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 87) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60~90%).
1H NMR(400MHz, CDC13) 60.92(t, J= 7.4Hz, 3H), 1.30~1.38(m, 1H), 1.57~1.64(m, 1H), 3.74(d, J= 9.2Hz, 1H), 4.80(br s, 2H), 5.40~5.50(m, 2H), 7.17~7.34(m, 3H)
Example 41: Synthesis of l-(2,4-dichlorophenyl)-(S)-l-hydroxy-3-methyl-butyl- (S)-2-carbamate(41)
Figure imgf000070_0003
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-3-methyl-(S,S)- 1 ,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 88) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane
(Preparation example69) to obtain the title compound (1.9g, yield 60-90%).
1H NMR(400MHz, CDC13) 6l.00(t, J = 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.85(br s, 2H), 5.40~5.43(m, 1H), 5.49~5.54(m, 1H), 7.30~7.50(m, 3H)
Example 42: Synthesis of l-(2,6-dichlorophenyl)-(S)-l-hydroxy-3-methyl-butyl- (S)-2-carbamate(42)
Figure imgf000071_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-3-methyl-(S,S)- 1 ,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 89) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane
(Preparation example69) to obtain the title compound (2.4g, yield 60-90%).
1H NMR(400MHz, CDC13) 6l .00(t, J= 7.2Hz, 6H), 1.73-1.79(m, 1H), 3.67~3.69(m, 1H), 4.85(br s, 2H), 5.40~5.43(m, 1H), 5.49~5.54(m, 1H), 7.16~7.33(m, 3H)
Example 43: Synthesis of l-(2,4-dichlorophenyl)-(S)-l-hydroxyhexyl-(S)-2- carbamate(43)
Figure imgf000071_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-(S,S)-l ,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 90) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.2g, yield 60-90%).
1H NMR(400MHz, CDC13) 60.89(t, J = 3.6Hz, 3H), 1.28~1.42(m, 4H), 1.52-1.59(m, 1H), 1.64~1.71(m, 1H), 2.98(d, J= 5.6Hz, 1H), 4.67(br s, 2H), 4.96~5.00(m, 1H), 5.17(t, J= 5.6Hz, 1H), 7.30-7.49(m 3H) Example 44: Synthesis of l-(2,6-dichlorophenyl)-(S)-l-hydroxyhexyl-(S)-2- carbamate(44)
The substantially same method as described in Example 1 was conducted, except that 1 - (2,6-dichlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 91) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.1 g, yield 60~90%)
1H NMR(400MHz, CDC13) 60.84(t, J= 7.0Hz, 3H), 1.20~1.35(m, 4H), 1.36~1.41(m, 1H), 1.59~1.63(m, 1H), 3.71(d, J= 10.0Hz, 1H), 4.74(br s, 2H), 5.40~5.44(m, 1H), 5.52~5.57(m, 1H), 7.17~7.35(m, 3H)
Example 45: Synthesis of l-(2,4-dichlorophenyl)-(R)-l-hydroxypropyl-(R)-2- carbamate(45)
Figure imgf000072_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 92) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.2g, yield 60-90%),
Ή NMR(400MHz, CDC13) 61.22(d, J= 6.4Hz, 3H), 4.16(br t, 1H) 4.96(br t, 3H), 5.07(t, J= 4.8Hz, 1H), 7.23~7.52(m, 3H)
Example 46: Synthesis of l-(2,6-dichlorophenyl)-(R)-l-hydroxypropyl-(R)-2- carbamate(46)
Figure imgf000073_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 93) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%),
1H NMR(400MHz, CDC13) 61.15(d, J= 6.4Hz, 3H), 3.66(d, J= 9.2Hz, 1H), 4.73(br s, 2H), 5.43(t, J= 9.0Hz, 1H), 5.62~5.69(m, 1H), 7.18~7.22(m, 3H),
Example 47: Synthesis of l-(2,3-dichlorophenyl)-(R)-l-hydroxypropyl-(R)-2- carbamate(47)
Figure imgf000073_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2,3-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 94) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.0g, yield 60-90%)
1H NMR(400MHz, CDC13) 51.15(d, J = 6.4Hz, 3H), 3.66(d, J = 9.2Hz, 1H), 4.73(br s, 2H), 5.43(t, J= 9.0Hz, 1H), 5.62~5.69(m, 1H), 7.18~7.22(m, 3H),
Example 48: Synthesis of l-(2,4-dichlorophenyl)-(R)-l-hydroxybutyl-(R)-2- carbamate(48)
Figure imgf000073_0003
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 95) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.3g, yield 60-90%).
1H NMR(400MHz, CDC13) 80.96(t, J= 7.4Hz, 3H), 1.58~1.74(m, 2H), 2.98(d, J =
5.6Hz, 1H) 4.68(br s, 2H), 5.59(dt, J= 5.2, 8.8Hz, 1H), 5.19(t, J= 5.4Hz, 1H), 7.30~7.50(m, 3H)
Example 49: Synthesis of l-(2,6-dichlorophenyl)-(R)-l-hydroxybutyl-(R)-2- carbamate(49)
Figure imgf000074_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 96) was used instead of 1 -(2-chlorophenyl)-(S,S)-l ,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.5g, yield 60-90%).
1H NMR(400MHz, CDC13) 60.92(t, J= 7.4Hz, 3H), 1.30~1.38(m, 1H), 1.57~1.64(m, 1H), 3.74(d, J= 9.2Hz, 1H), 4.80(br s, 2H), 5.40~5.50(m, 2H), 7.17~7.34(m, 3H)
Example 50: Synthesis of l-(2,4-dichlorophenyl)-(R)-l-hydroxy-3-methyl-butyl- (R)-2-carbamate(50)
Figure imgf000074_0002
The substantially same method as described in Example 1 was conducted, except that 1 - (2,4-dichlorophenyl)-3-methyl-(R,R)-l ,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 97) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane
(Preparation example69) to obtain the title compound (2.8g, yield 60~90%).
Ή NMR(400MHz, CDC13) 61.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.85(br s, 2H), 5.40~5.43(m, 1H), 5.49~5.54(m, 1H), 7.30~7.50(m, 3H)
Example 51: Synthesis of l-(2,6-dichlorophenyl)-(R)-l-hydroxy-3-methyl-butyl- (R)-2-carbamate(51)
Figure imgf000075_0001
The substantially same method as described in Example 1 was conducted, except that 1 (2,6-dichlorophenyl)-3-methyl-(R,R)- 1 ,2-(Bis-trimethylsilanyloxy)butane (Preparation Exampl 98) was used instead of l-(2-chlorophenyl)-(S,S)-l ,2-(Bis-trimethylsilanyloxy) propane
(Preparation example69) to obtain the title compound (2.6g, yield 60-90%).
1H NMPv(400MHz, CDC13) 6l.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.85(br s, 2H), 5.40~5.43(m, 1H), 5.49~5.54(m, 1H), 7.16~7.33(m, 3H)
Example 52: Synthesis of l-(2,4-dichlorophenyl)-(R)-l-hydroxyhexyl-(R)-2- carbamate(52)
Figure imgf000075_0002
The substantially same method as described in Example 1 was conducted, except that 1 - (2,4-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 99) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.5g, yield 60-90%).
1H NMR(400MHz, CDC13) 60.89(t, J= 3.6Hz, 3H), 1.28~1.42(m, 4H), 1.52~1.59(m, 1H), 1.64~1.71(m, 1H), 2.98(d, J= 5.6Hz, 1H), 4.67(br s, 2H), 4.96~5.00(m, 1H), 5.17(t, J = 5.6Hz, 1H), 7.30~7.49(m, 3H)
Example 53: Synthesis of l-(2,6-dichlorophenyI)-(R)-l-hydroxyhexyl-(R)-2- carbamate(53)
Figure imgf000075_0003
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 100) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.4g, yield 60-90%).
1H NMR(400MHz, CDC13) 60.84(t, J= 7.0Hz, 3H), 1.20~1.35(m, 4H), 1.36~1.41(m, 1H), 1.59~1.63(m, 1H), 3.71(d, J = 10.0Hz, 1H), 4.74(br s, 2H), 5.40~5.44(m, 1H), 5.52~5.57(m, 1H), 7.17~7.35(m, 3H)
Example 54: Synthesis of l-(2,4-dichlorophenyl)-l-hydroxypropyl-2- carbamate(54)
Figure imgf000076_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 101) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60~90%).
1H NMR(400MHz, CDC13) 6l .22(d, J= 6.4Hz, 3H), 4.16(br t, 1H) 4.96(br t, 3H), 5.07(t, J= 4.8Hz, 1H), 7.23~7.52(m, 3H)
Example 55: Synthesis of l-(2,6-dichlorophenyl)-l-hydroxypropyl-2- carbamate(55)
Figure imgf000076_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 102) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.4g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.15(d, J= 6.4Hz, 3H), 3.66(d, J= 9.2Hz, 1H), 4.73(br s, 2H), 5.43(t, J= 9.0Hz, 1H), 5.62~5.69(m, 1H), 7.18~7.22(m, 3H), Example 56: Synthesis of l-(2,3-dichlorophenyI)-l-hydroxypropyl-2- carbamate(56)
Figure imgf000077_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,3-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 103) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.6g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.15(d, J = 6.4Hz, 3H), 3.66(d, J = 9.2Hz, 1H), 4.73(br s, 2H), 5.43(t, J= 9.0Hz, 1H), 5.62~5.69(m, 1H), 7.18~7.22(m, 3H),
Example 57: Synthesis of l-(2,4-dichlorophenyl)-l-hydroxybutyl-2-carbamate(57)
Figure imgf000077_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 104) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%).
1H NMPv(400MHz, CDC13) 60.96(t, J= 7.4Hz, 3H), 1.58~1.74(m, 2H), 2.98(d, J =
5.6Hz, 1H) 4.68(br s, 2H), 5.59(dt, J= 5.2, 8.8Hz, 1H), 5.19(t, J= 5.4Hz, 1H), 7.30~7.50(m, 3H)
Example 58: Synthesis of l-(2,6-dichlorophenyl)-l-hydroxybutyl-2-carbamate(58)
Figure imgf000077_0003
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 105) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.4g, yield 60-90%). 1H NMR(400MHz, CDC13) 60.92(t, J= 7.4Hz, 3H), 1.30~1.38(m, 1H), 1.57~1.64(m, 1H), 3.74(d, J= 9.2Hz, 1H), 4.80(br s, 2H), 5.40~5.50(m, 2H), 7.17~7.34(m, 3H)
Example 59: Synthesis of l-(2,4-dichlorophenyl)-l-hydroxy-3-methyl-butyl-2- carbamate(59)
Figure imgf000078_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-3 -methyl- l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 106) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.9g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.85(br s, 2H), 5.40~5.43(m, 1H), 5.49~5.54(m, 1H), 7.30~7.50(m, 3H)
Example 60: Synthesis of l-(2,6-dichlorophenyl)-l-hydroxy-3-methyl-butyl-2- carbamate(60)
Figure imgf000078_0002
The substantially same method as described in Example 1 was conducted, except that 1 - (2,6-dichlorophenyl)-3 -methyl- l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 107) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%).
1H NMR(400MHz, CDC13) 61.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.85(br s, 2H), 5.40~5.43(m, 1H), 5.49~5.54(m, 1H), 7.16~7.33(m, 3H)
Example 61: Synthesis of l-(2,4-dichlorophenyl)-l-hydroxyhexyl-2-carbamate(61)
Figure imgf000078_0003
The substantially same method as described in Example 1 was conducted, except that 1- (2,4-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 108) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.6g, yield 60-90%).
1H NMR(400MHz, CDC13) δ0.89(ΐ, J= 3.6Hz, 3H), 1.28~1.42(m, 4H), 1.52~1.59(m, 1H), 1.64~1.71(m, 1H), 2.98(d, J= 5.6Hz, 1H), 4.67(br s, 2H), 4.96~5.00(m, 1H), 5.17(t, J= 5.6Hz, 1H), 7.30~7.49(m, 3H)
Example 62: Synthesis of l-(2,6-dichlorophenyl)-l-hydroxyhexyl-2-carbamate(62)
Figure imgf000079_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2,6-dichlorophenyl)-l,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 109) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.5g, yield 60~90%).
1H NMR(400MHz, CDC13) 60.84(t, J = 7.0Hz, 3H), 1.20-1.35(m, 4H), 1.36-1.41 (m, 1H), 1.59~1.63(m, 1H), 3.71(d, J = 10.0Hz, 1H), 4.74(br s, 2H), 5.40~5.44(m, 1H), 5.52~5.57(m, 1H), 7.17-7.35(m, 3H)
Example 63: Synthesis of l-(2-fluorophenyl)-(S)-l-hydroxypropyl-(S)-2- carbamate(63)
Figure imgf000079_0002
The substantially same method as described in Example 1 was conducted, except that 1- (2-fluorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 110) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.8g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.19(d, J=5.2Hz, 3H), 2.93(d, J=4.4Hz, 1H), 4.71(br s, 2H), 4.99~5.06(m, H), 7.04-7.48(m, 4H) Example 64: Synthesis of l-(2-fluorophenyl)-(R)-l-hydroxypropyl-(R)-2- carbamate(64)
Figure imgf000080_0001
The substantially same method as described in Example 1 was conducted, except that 1-
(2-fluorophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 111) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.6g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.19(d, J=5.2Hz, 3H), 2.93(d, J=4.4Hz, 1H), 4.71(br s, 2H), 4.99~5.06(m, H), 7.04~7.48(m, 4H)
Example 65: Synthesis of l-(2-iodophenyl)-(S)-l-hydroxypropyl-(S)-2- carbamate(65)
Figure imgf000080_0002
The substantially same method as described in Example 1 was conducted, except that 1-
(2-iodophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 112) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.2g, yield 60-90%).
Ή NMR(400MHz, CDC13) 51.27(d, J=6.4Hz, 3H), 3.09(br s, 1H), 4.83(br s, 2H), 5.00-5.10(m, 2H), 7.00~7.76(m, 4H)
Example 66: Synthesis of l-(2-iodophenyl)-(R)-l-hydroxypropyl-(R)-2- carbamate(66)
Figure imgf000080_0003
The substantially same method as described in Example 1 was conducted, except that 1-
(2-iodophenyl)-(R,R)-l,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 113) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (1.7g, yield 60-90%).
1H NMR(400MHz, CDC13) 51.27(d, J=6.4Hz, 3H), 2.95(d, J=3.6Hz, 1H), 4.73(br s, 2H), 5.01-5. ll(m, 2H), 7.01~7.86(m, 4H)
Example 67: Synthesis of l-(2-iodophenyl)-(S)-l-hydroxybutyI-(S)-2- carbamate(67)
Figure imgf000081_0001
The substantially same method as described in Example 1 was conducted, except that 1- (2-iodophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 114) was used instead of l-(2-chlorophenyl)-(S,S)-l,2-(Bis-trimethylsilanyloxy) propane (Preparation example69) to obtain the title compound (2.1 g, yield 60-90%).
Ή NMR(400MHz, CDC13) 51.27(d, J=6.4Hz, 3H), 3.09(br s, 1H), 4.83(br s, 2H), 5.00-5.10(m, 2H), 7.00~7.76(m, 4H)
Example 68: Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- carbamate(68)
Figure imgf000081_0002
l-(2-chlorophenyl)-(S,S)-l,2-propanediol(2.33g, Preparation example 14) obtained in Preparation Example 14, tetrahydrofuran (THF, 12ml), and carbonyldiimidazole (CD I, 3.04g) were put into a flask and stirred at the room temperature. After approximately 3 hours, ammonia solution (NH4OH, 4ml) was added thereto. When the reaction was completed, the obtained product was washed with 1M HC1 solution and ethylacetate (EA). The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgS04), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography, to obtain the title compound (0.28g, yield 10-30%). Ή NMR(400MHz, CDC13) 61.24(d, J= 6.8Hz, 3H), 2.13(d, J= 4.4Hz, 1H), 4.12~4.16(m, 1H), 4.85(br s, 2H), 5.98(d, J= 5.6Hz, 1H), 7.24~7.43(m, 4H)
Example 69: Synthesis of l-(2-chlorophenyI)-(R)-2-hydroxypropyl-(R)-l- carbamate(69)
Figure imgf000082_0001
The substantially same method as described in Example 68 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-propanediol (Preparation Example 15) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol (Preparation example 14) to obtain the title compound (0.77g, yield 16%).
1H NMR(400MHz, CDC13) 61.24(d, J= 6.4Hz, 3H), 2.04(d, J= 4.8Hz, 1H),
4.1 l~4.18(m, 1H), 4.74(br s, 2H), 6.00(d, J= 5.6Hz, 1H), 7.24~7.43(m, 4H)
Example 70: Synthesis of l-(2-chlorophenyl)-2-hydroxypropyl-l-carbamate(70)
Figure imgf000082_0002
The substantially same method as described in Example 68 was conducted, except that l-(2-chlorophenyl)-(R,R)-l,2-propanediol (Preparation Example 16) was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol (Preparation example 14) to obtain the title compound (0.16g, yield 10-30%).
1H NMR(400MHz, CDC13) 51.24(d, J - 6.4Hz, 3H), 2.04(d, J = 4.8Hz, 1H), 4.11~4.18(m, 1H), 4.74(br s, 2H), 6.00(d, J= 5.6Hz, 1H), 7.24~7.43(m, 4H)
Example 71: Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- methylcarb amate(71 )
Figure imgf000083_0001
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 15, to obtain the title compound (0.70g, yield 10-30%).
1H NMR(400MHz, CDC13) 51.21(d, J=6.4Hz, 3H), 2.80(d, J=4.8Hz, 3H), 3.12(s, 1H),
4.09~4.16(m, 1H), 4.86(br s, 1H), 5.99(d, J= 6.0Hz, 1H), 7.23~7.40(m, 4H)
Example 72: Synthesis of l-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-l- N- methylcarbamate(72)
Figure imgf000083_0002
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 22, to obtain the title compound (0.69g, yield 10-30%).
1H NMR(400MHz, CDC13) 61.21(d, J=6.4Hz, 3H), 2.80(d, J=4.8Hz, 3H), 3.12(s, 1H), 4.09~4.16(m, 1H), 4.86(br s, 1H), 5.99(d, J= 6.0Hz, 1H), 7.23~7.40(m, 4H)
Example 73: Synthesis of l-(2-chlorophenyl)-2-hydroxypropyl-l- N- methylcarbamate(73)
Figure imgf000083_0003
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 29, to obtain the title compound (0.73g, yield 10-30%).
1H NMR(400MHz, CDC13) δ 1.22(d, J=6Hz, 3H), 2.15(d, J=4Hz, 1H), 2.8 l(d, J=5Hz, 3H), 4.12(dd, J=6Hz, 1H), 4.83(br s, 1H), 6.00(d, J=6Hz, 1H), 7.23~7.41(m, 4H) Example 74: Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- propylcarbamate(74)
Figure imgf000084_0001
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 16, to obtain the title compound (0.15g, yield 10-30%).
1H NMR(400MHz, CDC13) δ 0.91 (t, J=7Hz, 3H), 1.22(d, J=6Hz, 3H), 1.52(dd, J=7Hz, 2H), 2.23(d, J=4Hz, IH), 3.09~3.21(m, 2H), 4.09~4.17(m, IH), 4.93(s, IH), 5.99(d, J=6Hz, IH), 7.23~7.47(m, 4H)
Example 75: Synthesis of l-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-l- N- propylcarbamate(75)
Figure imgf000084_0002
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 23, to obtain the title compound (0.04g, yield 10-30%).
1H NMR(400MHz, CDCI3) δ 0.9 l(t, J=7Hz, 3H), 1.22(d, J=6Hz, 3H), 1.52(dd, J=7Hz, 2H), 2.23(d, J=4Hz, IH), 3.09~3.21(m, 2H), 4.09~4.17(m, IH), 4.93(s, IH), 5.99(d, J=6Hz, IH), 7.23~7.47(m, 4H)
Example 76: Synthesis of l-(2-chlorophenyl)-2-hydroxypropyl-l- N- propylcarbamate(76)
Figure imgf000084_0003
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 30, to obtain the title compound (0.15g, yield 10-30%).
1H NMR(400MHz, CDC13) δ 0.91(t, J=7Hz, 3H), 1.22(d, J=6Hz, 3H), 1.52(dd, J=7Hz, 2H), 2.23(d, J=4Hz, 1H), 3.09~3.21(m, 2H), 4.09~4.17(m, 1H), 4.93(s, 1H), 5.99(d, J=6Hz, 1H), 7.23~7.47(m, 4H)
Example 77: Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- isopropylcarbamate(77)
Figure imgf000085_0001
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 17, to obtain the title compound (0.42g, yield 10-30%).
1H NMR(400MHz, CDC13) 51.10(d, J=6.0Hz, 3H), 1.15~1.19(m, 6H), 2.41(s, 1H), 3.76~4.08(m, 1H), 4.34(s, 1H), 4.83(br s 1H), 5.95(d, J=5.3Hz, 1H), 7.19~7.39(m, 4H)
Example 78: Synthesis of l-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-l- N- isopropylcarbamate(78)
Figure imgf000085_0002
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 24, to obtain the title compound (0.5g, yield 10-30%).
1H NMR(400MHz, CDC13) 61.13(d, J=6Hz, 3H), 1.20(dd, J=9.2Hz, 6H), 2.23(s, 1H), 3.77~3.82(m, 1H), 4.10(s, 1H), 4.76(br s, 1H), 5.98(d, J=5.6Hz, 1H), 7.23-7.41 (m, 4H)
Example 79: Synthesis of l-(2-chlorophenyI)-2-hydroxypropyl-l- N- isopropylcarbamate(79)
Figure imgf000086_0001
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 31, to obtain the title compound (0.09g, yield 10-30%).
1H NMR(400MHz, CDC13) δ 1.14(d, J=6Hz, 3H), 1.21(dd, J=6Hz, 6H), 2.16(d, J=5Hz, 1H), 3.81(t, J=6Hz, 1H), 4.11(d, J=5Hz, 1H), 4.73(br s, 1H), 5.98(d, J=5Hz, 1H), 7.24~741(m, 4H)
Example 80: Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- cyclopropylcarbamate(80)
Figure imgf000086_0002
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 18, to obtain the title compound (0.53g, yield 10-30%).
1H NMR(400MHz, CDC13) 50.53~0.60(m, 2H), 0.74(s, 2H), 1.21(d, J=6.0Hz, 3H), 2.19(s, 1H), 2.59(s, 1H), 4.11~4.15(m, 1H), 5.13(br s, 1H), 5.99(d, J=5.20Hz, 1H), 7.23~7.40(m, 4H)
Example 81: Synthesis of l-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-l- N- cy clopropylcarb amate(81)
Figure imgf000086_0003
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 25, to obtain the title compound (0.58g, yield
10%). 1H NMR(400MHz, CDC13) 50.53~0.60(m, 2H), 0.74(s, 2H), 1.21(d, J=6.0Hz, 3H), 2.19(s, 1H), 2.59(s, 1H), 4.11~4.15(m, 1H), 5.13(br s, 1H), 5.99(d, J=5.20Hz, 1H), 7.23~7.40(m, 4H)
Example 82: Synthesis of l-(2-chlorophenyl)-2-hydroxypropyl-l- N- cycIopropylcarbamate(82)
Figure imgf000087_0001
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 32, to obtain the title compound (0.38g, yield
14%).
1H NMR(400MHz, CDC13) δ 0.71(s, 2H), 1.19(d, J=6Hz, 3H), 2.45(S, 1H), 2.57(S, 1H), 4.08~4.12(m, 1H), 5.26(s, 1H), 5.97(d, J=4Hz, 1H), 7.22~7.54(m, 4H)
Example 83: Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- cyclohexylcarbamate(83)
Figure imgf000087_0002
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 19, to obtain the title compound (0.24g, yield 10-30%).
Ή NMR(400MHz, CDC13) 51.10~1.39(m, 7H), 1.61(s, 3H), 1.71~1.74(m, 2H), 1.87(d, J=11.2Hz, 1H), 2.48(d, J=10.8Hz, 1H), 3.46(t, J=4Hz, 1H), 4.10~4.11(m, 1H), 4.80(br s 1H), 5.97(d, J=5.6Hz, 1H), 7.23~7.41(m, 4H)
Example 84: Synthesis of l-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-l- N- cyclohexylcarbamate(84)
Figure imgf000088_0001
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 26, to obtain the title compound (0.35g, yield
10%).
1H NMR(400MHz, CDC13) 51.10~1.39(m, 7H), 1.61(s, 3H), 1.71~1.74(m, 2H), 1.87(d, J=11.2Hz, IH), 2.48(d, J=10.8Hz, IH), 3.46(t, J=4Hz, IH), 4.10~4.11(m, IH), 4.80(br s IH), 5.97(d, J=5.6Hz, IH), 7.23~7.41(m, 4H)
Example 85: Synthesis of l-(2-chlorophenyl)-2-hydroxypropyl-l- N- cyclohexylcarbamate(85)
Figure imgf000088_0002
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 33, to obtain the title compound (0.26g, yield 10%).
1H NMR(400MHz, CDC13) δ 1.12~1.19(m, 3H), 1.22(d, J=6Hz, 3H), 1.27~1.37(m, IH), 1.71(t, J=6Hz, 2H), 1.86~1.88(m, IH), 1.97~2.00(m, IH), 2.18(d, J=4Hz, IH), 3.47(S, IH), 4.12(t, J=6Hz, IH), 4.78(S, IH), 5.97(d, J=6Hz, IH), 7.23~7.40(m, 4H)
Example 86: Synthesis of l-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-l- N- benzylcarbamate(86)
Figure imgf000088_0003
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 20, to obtain the title compound (0.19g, yield
10-30%). Ή NMR(400MHz, CDC13) δ 1.23(d, J=6Hz, 3H), 2.16(d, J=4Hz, 1H), 4.12(t, J=6Hz, 1H), 4.31~4.44(m, 2H), 5.22(br S, 1H), 6.04(d, J=6Hz, 1H), 7.27~7.42(m, 9H)
Example 87: Synthesis of l-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-l- N- benzylcarbamate(87)
Figure imgf000089_0001
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 27, to obtain the title compound (0.07g, yield 10-30%).
Ή NMR(400MHz, CDC13) δ 1.23(d, J=6Hz, 3H), 2.16(d, J=4Hz, 1H), 4.12(t, J=6Hz, 1H), 4.31~4.44(m, 2H), 5.22(br S, 1H), 6.04(d, J=6Hz, 1H), 7.27~7.42(m, 9H)
Example 88: Synthesis of l-(2-chlorophenyl)-2-hydroxypropyl-l- N- benzylcarbamate(88)
Figure imgf000089_0002
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 34, to obtain the title compound (0.2 lg, yield 14%).
Ή NMR(400MHz, CDC13) δ 1.23(d, J=6Hz, 3H), 2.16(d, J=4Hz, 1H), 4.12(t, J=6Hz, 1H), 4.31~4.44(m, 2H), 5.22(br S, 1H), 6.04(d, J=6Hz, 1H), 7.27~7.42(m, 9H)
Example 89: Synthesis of l-(2,4-dichlorophenyl)-(S)-2-hydroxypropyl-(S)-l- carbamate(89)
Figure imgf000089_0003
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-propanediol(Preparation example 26)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.05g, yield 10-30%).
Ή NMR(400MHz, CDC13) 6l .l3(d, J= 6.8Hz, 3H), 2.49(d, J= 4.0Hz, 1H),
4.66~4.74(m, 1H), 4.76(br s, 2H), 6.20(d, J = 8.8Hz, 1H), 7.30(d, J=8.4Hz, 1H), 7.39(d, J=2.0Hz, 2H), 7.50(dd, J=8.4Hz, 2.0Hz, 1H)
Example 90: Synthesis of l-(2,6-dichlorophenyl)-(S)-2-hydroxypropyl-(S)-l- carbamate(90)
Figure imgf000090_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-propanediol(Preparation example 38)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.07& yield 24%).
lH NMR(400MHz, CDCI3) fil . l3(d, J= 6.8Hz, 3H), 2.49(d, J= 4.0Hz, 1H),
4.66~4.74(m, 1H), 4.76(br s, 2H), 6.20(d, J= 8.8Hz, 1H), 7.25~7.40(m, 3H)
Example 91: Synthesis of l-(2,3-dichlorophenyl)-(S)-2-hydroxypropyl-(S)-l- carbamate(91)
Figure imgf000090_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,3-dichlorophenyl)-(S,S)-l ,2-propanediol(Preparation example 57)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.08g, yield 10-30%). Ή NMR(400MHz, CDC13) 61.15(d, J= 6.4Hz, 3H), 3.66(d, J = 9.2Hz, IH), 4.73(br s, 2H), 5.43(t, J= 9.0Hz, IH), 5.62~5.69(m, IH), 7.18~7.22(m, 3H),
Example 92: Synthesis of l-(2,4-dichlorophenyl)-(S)-2-hydroxybutyl-(S)-l- carbamate(92)
Figure imgf000091_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-butanediol(Preparation example 29)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.07g, yield 10-30%).
1H NMR(400MHz, CDC13) 60.77(t, J= 7.4Hz, 3H), 0.92~1.01(m, IH), 1.18~1.28(m, IH), 4.06-4.13(m, IH), 4.96(d, J= 6.0Hz, IH), 5.91(d, J= 8.8Hz, IH), 6.4(br s, 2H),
7.30-7.50(m, 3H)
Example 93: Synthesis of l-(2,6-dichlorophenyl)-(S)-2-hydroxybutyl-(S)-l- carbamate(93)
Figure imgf000091_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-butanediol(Preparation example 41)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (O.l lg, yield 29%).
1H NMR(400MHz, CDC13) 60.77(t, J= 7.4Hz, 3H), 0.92~1.01(m, IH), 1.18~1.28(m, IH), 4.06~4.13(m, IH), 4.96(d, J=6.0Hz, IH), 5.91(d, J=8.8Hz, IH), 6.4(br s, 2H), 7.25~7.40(m, 3H) Example 94: Synthesis of l-(2,4-dichlorophenyl)-(S)-2-hydroxy-3-methyl-butyl-(S)- l-carbamate(94)
Figure imgf000092_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-(S,S)-l,2-butanediol(Preparation example 32)was used instead of 1 -(2-chlorophenyl)-(S,S)- 1 ,2-propanediol(Preparation example 14), to obtain the title compound (0.01 g, yield 10-30%).
1H NMR(400MHz, CDC13) 51.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.96(d, J=6.0Hz, 1H), 5.91(d, J=8.8Hz, 1H), 6.42(br s, 2H), 7.30~7.50(m, 3H)
Example 95: Synthesis of l-(2,6-dichlorophenyl)-(S)-2-hydroxy-3-methyl-butyl-(S)- l-carbamate(95)
Figure imgf000092_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-(S,S)-l,2-butanediol(Preparation example 44)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.03 g, yield 10-30%).
Ή NMR(400MHz, CDC13) 61.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67-3.69(m, 1H), 4.96(d, J=6.0Hz, 1H), 5.91(d, J=8.8Hz, 1H), 6.42(br s, 2H), 7.25~7.40(m, 3H)
Example 96: Synthesis of l-(2,4-dichlorophenyl)-(S)-2-hydroxyhexyl-(S)-l- carbamate(96)
Figure imgf000092_0003
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(S,S)-l,2-hexanediol(Preparation example 35)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.2 lg, yield 10-30%).
Ή NMR(400MHz, CDC13) 60.85(t, J=7.2Hz, 3H), 1.18~1.33(m, 4H), 1.48~1.55(m, 2H), 2.35(d, J=4.4Hz, 1H), 4.45~4.50(m, 1H), 4.76(br s, 2H), 6.21(d, J=8.4Hz, 1H), 7.30~7.50(m, 3H)
Example 97: Synthesis of l-(2,6-dichlorophenyl)-(S)-2-hydroxyhexyl-(S)-l- carbamate(97)
Figure imgf000093_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(S,S)-l,2-hexanediol(Preparation example 47)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.06g, yield 29%).
lH NMR(400MHz, CDC13) 60.85(t, J= 7.2Hz, 3H), 1.18~1.33(m, 4H), 1.48~1.55(m, 2H), 2.35(d, J= 4.4Hz, 1H), 4.45~4.50(m, 1H), 4.76(br s, 2H), 6.21 (d, J=8.4Hz, 1H),
7.16~7.34(m, 3H)
Example 98: Synthesis of l-(2,4-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-l- carbamate(98)
Figure imgf000093_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example 27)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.04g, yield 10-30%). 1H NMR(400MHz, CDC13) 51.13(d, J=6.8Hz, 3H), 2.49(d, J=4.0Hz, 1H), 4.66~4.74(m, 1H), 4.76(br s, 2H), 6.20(d, J=8.8Hz, 1H), 7.30~7.50(m, 3H)
Example 99: Synthesis of l-(2,6-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-l- carbamate(99)
Figure imgf000094_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example 39)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.09g, yield 10-30%).
1H NMR(400MHz, CDC13) 61.13(d, J= 6.8Hz, 3H), 2.49(d, J= 4.0Hz, 1H),
4.66~4.74(m, 1H), 4.76(br s, 2H), 6.20(d, J= 8.8Hz, 1H), 7.25~7.40(m, 3H)
Example 100: Synthesis of l-(2,3-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-l- carbamate(lOO)
Figure imgf000094_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,3-dichlorophenyl)-(R,R)-l,2-propanediol(Preparation example 58)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.25g, yield 10-30%).
Ή NMR(400MHz, CDC13) 61.15(d, J= 6.4Hz, 3H), 3.66(d, J= 9.2Hz, 1H), 4.73(br s, 2H), 5.43(t, J= 9.0Hz, 1H), 5.62~5.69(m, 1H), 7.18~7.22(m, 3H),
Example 101: Synthesis of l-(2,4-dichlorophenyl)-(R)-2-hydroxybutyl-(R)-l- carbamate(lOl)
Figure imgf000095_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-butanediol(Preparation example 30)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4), to obtain the title compound (0.08g, yield 10-30%).
1H NMR(400MHz, CDC13) 60.77(t, J= 7.4Hz, 3H), 0.92~1.01(m, 1H), 1.18~1.28(m, 1H), 4.06~4.13(m, 1H), 4.96(d, J= 6.0Hz, 1H), 5.91(d, J= 8.8Hz, lH), 6.4(br s, 2H),
7.30~7.50(m, 3H)
Example 102: Synthesis of l-(2,6-dichlorophenyl)-(R)-2-hydroxybutyl-(R)-l- carbamate(102)
Figure imgf000095_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-butanediol(Preparation example 42)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.09g, yield 10-30%). 1H NMR(400MHz, CDC13) 80.77(t, J= 7.4Hz, 3H), 0.92~1.01(m, 1H), 1.18~1.28(m, 1H), 4.06~4.13(m, 1H), 4.96(d, J= 6.0Hz, 1H), 5.91(d, J= 8.8Hz, 1H), 6.4(br s, 2H), 7.25~7.40(m, 3H)
Example 103: Synthesis of l-(2,4-dichlorophenyl)-(R)-2-hydroxy-3-methyl-butyl- (R)-l-carbamate(103)
Figure imgf000095_0003
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-(R,R)-l,2-propanediol(Preparation example 33)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4), to obtain the title compound (O.Olg, yield 10-30%).
1H NMR(400MHz, CDC13) 61.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.96(d, J=6.0Hz, 1H), 5.91(d, J=8.8Hz, 1H), 6.42(br s, 2H), 7.30~7.50(m, 3H)
Example 104: Synthesis of l-(2,6-dichlorophenyl)-(R)-2-hydroxy-3-methyl-butyl-
(R)-l-carbamate(104)
Figure imgf000096_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-3-methyl-(R,R)-l,2-propanediol(Preparation example 45)was used instead of l-(2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation examplel4), to obtain the title compound (O.Olg, yield 10-30%).
Ή NMR(400MHz, CDC13) 61.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.96(d, J=6.0Hz, 1H), 5.91(d, J=8.8Hz, 1H), 6.42(br s, 2H), 7.25~7.40(m, 3H)
Example 105: Synthesis of l-(2,4-dichlorophenyl)-(R)-2-hydroxyhexyl-(R)-l- carbamate(105)
Figure imgf000096_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-(R,R)-l,2-hexanediol(Preparation example 36)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.2 lg, yield 10-30%).
Ή NMR(400MHz, CDC13) 50.85(t, J=7.2Hz, 3H), 1.18~1.33(m, 4H), 1.48-1.55(m, 2H), 2.35(d, J=4.4Hz, 1H), 4.45~4.50(m, 1H), 4.76(br s, 2H), 6.21(d, J=8.4Hz, 1H), 7.30~7.50(m, 3H) Example 106: Synthesis of l-(2,6-dichlorophenyl)-(R)-2-hydroxyhexyl-(R)-l- carbamate(106)
Figure imgf000097_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-(R,R)-l,2-hexanediol(Preparation example 48)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.12g, yield 10-30%).
1H NMR(400MHz, CDC13) 60.85(t, J= 7.2Hz, 3H), 1.18~1.33(m, 4H), 1.48~1.55(m, 2H), 2.35(d, J= 4.4Hz, 1H), 4.45~4.50(m, 1H), 4.76(br s, 2H), 6.21(d, J= 8.4Hz, 1H),
7.16~7.34(m, 3H)
Example 107: Synthesis of l-(2,4-dichlorophenyl)-2-hydroxypropyl-l- carbamate(107)
Figure imgf000097_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-l,2-propanediol(Preparation example 28)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.05g, yield 10-30%).
1H NMR(400MHz, CDC13) 61.13(d, J=6.8Hz, 3H), 2.49(d, J=4.0Hz, 1H), 4.66~4.74(m, 1H), 4.76(br s, 2H), 6.20(d, J=8.8Hz, 1H), 7.30~7.50(m, 3H)
Example 108: Synthesis of l-(2,6-dichlorophenyl)-2-hydroxypropyl-l- carbamate(108)
Figure imgf000097_0003
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-l,2-propanediol(Preparation example 40)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.06g, yield 10-30%).
1H NMR(400MHz, CDC13) 61.13(d, J= 6.8Hz, 3H), 2.49(d, J= 4.0Hz, 1H),
4.66~4.74(m, 1H), 4.76(br s, 2H), 6.20(d, J= 8.8Hz, 1H), 7.25~7.40(m, 3H)
Example 109: Synthesis of l-(2,3-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-l- carbamate(109)
Figure imgf000098_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,3-dichlorophenyl)-l,2-propanediol(Preparation example 59)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.02g, yield 10-30%).
1H NMR(400MHz, CDC13) 51.15(d, J= 6.4Hz, 3H), 3.66(d, J= 9.2Hz, 1H), 4.73(br s, 2H), 5.43(t, J= 9.0Hz, 1H), 5.62~5.69(m, 1H), 7.18~7.22(m, 3H),
Example 110: Synthesis of l-(2,4-dichlorophenyl)-2-hydroxybutyl-l- carbamate(llO)
Figure imgf000098_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-l,2-butanediol(Preparation example 31 )was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.07g, yield 10-30%).
Ή NMR(400MHz, CDC13) 60.77(t, J=7.4Hz, 3H), 0.92~1.01(m, 1H), 1.18~1.28(m, 1H), 4.06~4.13(m, 1H), 4.96(d, J=6.0Hz, 1H), 5.91(d, J=8.8Hz, 1H), 6.4(br s, 2H), 7.30-7.50(m, 3H) Example 111: Synthesis of l-(2,6-dichlorophenyI)-2-hydroxybutyl-l- carbamate(lll)
Figure imgf000099_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-l,2-butanediol(Preparation example 43)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.1 Og, yield 10-30%).
1H NMR(400MHz, CDC13) 60.77(t, J= 7.4Hz, 3H), 0.92~1.01(m, 1H), 1.18~1.28(m, 1H), 4.06~4.13(m, 1H), 4.96(d, J= 6.0Hz, 1H), 5.91(d, J= 8.8Hz, 1H), 6.4(br s, 2H),
7.25~7.40(m, 3H)
Example 112: Synthesis of l-(2,4-dichlorophenyl)-2-hydroxy-3-methyl-butyl-l- carbamate(112)
Figure imgf000099_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-3-methyl-l,2-propanediol(Preparation example 34)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.04g, yield 10-30%).
1H NMR(400MHz, CDC13) 81.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, 1H), 3.67~3.69(m, 1H), 4.96(d, J=6.0Hz, 1H), 5.91(d, J=8.8Hz, 1H), 6.42(br s, 2H), 7.30~7.50(m, 3H)
Example 113: Synthesis of l-(2,6-dichlorophenyl)-2-hydroxy-3-methyl-butyl-l- carbamate(113)
Figure imgf000099_0003
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-3 -methyl- l,2-propanediol(Preparation example 46)was used instead of 1- (2-chlorophenyl)-(S,S)-l,2-propanediol(Preparation exampleH), to obtain the title compound (O.Olg, yield 10-30%).
1H NMR(400MHz, CDC13) 81.00(t, J= 7.2Hz, 6H), 1.73~1.79(m, IH), 3.67~3.69(m, IH), 4.96(d, J=6.0Hz, IH), 5.91(d, J=8.8Hz, IH), 6.42(br s, 2H), 7.25~7.40(m, 3H)
Example 114: Synthesis of l-(2,4-dichlorophenyl)-2-hydroxyhexyl-l- carbamate(114)
Figure imgf000100_0001
The substantially same method as described in Example 68 was conducted, except that l-(2,4-dichlorophenyl)-l,2-hexanediol(Preparation example 37)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.2 lg, yield 10-30%).
1H NMR(400MHz, CDC13) 60.85(t, J=7.2Hz, 3H), 1.18~1.33(m, 4H), 1.48~1.55(m, 2H), 2.35(d, J=4.4Hz, IH), 4.45~4.50(m, IH), 4.76(br s, 2H), 6.21(d, J=8.4Hz, IH), 7.30~7.50(m, 3H)
Example 115: Synthesis of l-(2,6-dichlorophenyl)-2-hydroxyhexyl-l- carbamate(115)
Figure imgf000100_0002
The substantially same method as described in Example 68 was conducted, except that l-(2,6-dichlorophenyl)-l,2-hexanediol(Preparation example 49)was used instead of l-(2- chlorophenyl)-(S,S)-l,2-propanediol(Preparation example 14), to obtain the title compound (0.12g, yield 10-30%). Ή NMR(400MHz, CDC13) 80.85(t, J= 7.2Hz, 3H), 1.18~1.33(m, 4H), 1.48~1.55(m, 2H), 2.35(d, J= 4.4Hz, 1H), 4.45~4.50(m, 1H), 4.76(br s, 2H), 6.21(d, J= 8.4Hz, 1H),
7.16~7.34(m, 3H) Compounds 1 to 115 produced in Examples 1 to 115 were summarized in following
Tables 1 and 2.
(Table 1) Compounds 1 to 67 having the structure of Chemical Formula 1 where 'A' is a carbamoyl derivative and 'B' is H
Figure imgf000101_0001
Figure imgf000102_0001
(Table 2) Compounds 68 to 115 having the structure of Chemical Formula 1 where 'A' 'B' is a carbamoyl derivative
Figure imgf000102_0002
Figure imgf000103_0001
Biological Experimental Example I : Measurement of Anti-epilepsy activity
In the MES test(Ref, G. Villetti et al. Neuropharmacology 40(2001) 866-878), an electrical stimulus(mice; 50mA, 60Hz, 0.2sec and rats; 150mA 60Hz, 0.2sec in the test animal) supplied by 11 A Shocker(IITC Life Science Company) was delivered through corneal electrodes. All mice or rats assigned to any electroshock at peak time were treated with each test compound sample which was dissolved in 30% PEG400 prepared by saline solvent applied to oral before the test. If the test animal stretching their hind limb in a straight line weren't observed in the MES test, the results indicate that the test sample had an anti-epilepsy activity. Three doses of the test sample were administered orally to over 18 mice (6 mice per dose) for evaluating the respective doses at which 50% of the animals are protected from seizure (ED50). The value of ED50 (median effective dose) is calculated by Litchfield and Wicoxon log-probit method which is a dose-response relationship. Then, the test results are shown in following Table 3. Experimental animal, male ICR mice and male SD rats, were purchased from OrientBio or Nara biotech, Korea, and housed 4-5 mice per a cage for 4-5 days. The range of mice body weight was used between 19 and 26 grams and range of rats body weight was used between 100 and 130 grams.
Biological Experimental Example II: Measurement of Anti-epilepsy activity through scPTZ
In this experiment, each test compound sample was formulated as described in Biological Experimental Example I, and administered intraperitoneally to test animals (mice; ICR or Rat; SD); Experimental animal, male ICR mice and male SD rats, were purchased from OrientBio or Nara biotech, Korea, and housed 4-5 mice per a cage for 4-5 days. The range of mice body weight was used between 19 and 26 grams and range of rats body weight was used between 100 and 130 grams. After Peak time (0.5, 1 , 2 and 4hr) from the administration, PTZ(Pentylenetetrazol) was administered subcutaneously in the concentration capable of inducing 97% intermittent convulsions (mice: 100~110mg/kg»bw, ΙΟ ί/g, or rats: 90-110 mg/kg«bw, 2 d/g). If clonic seizure was not observed for at least 3 seconds in the PTZ administered animal, it can be considered that the test compound has anti-epilepsy activity. The median effective dose (ED50) is determined using 6 animals per a concentration (total three different concentrations), and calculated by Litchfield and Wicoxon log-probit method which is a dose-response relationship. The obtained results are shown in following Table 3.
Biological Experimental Example III: Measurement of Neurotoxicity
The measurement of neurotoxicity of the test compounds was conducted by the method of Dunham and Miya [Dunham, N.W. and Miya, T.S. 1957. A note on a simple apparatus for detecting neurological deficit in rats and mice. J.Am.Pharm.Assoc. (Baltimore) 46: 208-209]. In the method, motor abilities of the test animals can be determined by observing whether the test animals can walk without falling from a rotator, thereby determining the value of neurotoxicity of each compound. Term "TD50" means the respective dose of the test compound at which 50% of the test animal exhibit neurotoxicity. They were pre-trained on the rotarod (Rotarod; Columbus instrument, rota-max, USA) at 6 rpm for 5 min 24 hr prior to the test. The peak time was determined by administration test material's random dose for 0.5, 1, 2, 4 hour. To evaluate the minimal neurotoxicity of the compound, the mice were placed on the Rotarod (rod circle; 3 Cm) at 6rpm and the test animal fails to maintain walking once or more during 1 minute, it can be regarded that the test animal exhibits neurotoxicity. The ratio of TD50 to ED50 (TD50/ED50) is called as a protective index, and useful as a parameter for comparison of pharmaceutical efficacy and neurotoxicity. The obtained results are shown in following Table 3.
[Statistical Analysis]
The obtained results are shown as mean±sem. The difference between the groups was statistically analyzed by ANOVA, and then, further examined by Dunnett's test or Bonferroni test. If p is less than 0.05, it was determined that the difference between the groups had statistical significance.
(Table 3) Measurement results of anti-epilepsy activity of compounds in the test animals
(Mice and Rats)
Figure imgf000105_0001
Figure imgf000106_0001
# a: Injection amount(mg/kg), Protection%(4 mice);
b: Injection amount(mg/kg), Protection%(6 Rats );
Biological Experimental Example IV: Measurement of pharmaceutical efficacy duration time through MES
The ED50 values according to time were measured in the test animals (mice and rats) after oral administration of test compound 1 as described in Biological Experimental Example I. The obtained results are shown in following Table 4 and Fig. 1.
(Table 4) Duration of MES test ED50(mg/kg), (po)
Figure imgf000106_0002
As shown in Table 4 and Fig. 1 , the test compound 1 exhibits the efficacy duration time of at least 12 hours in both of the tested rats and mice.
Biological Experimental Example V: Measurement of pharmaceutical efficacy duration time through scPTZ
The ED50 values according to time were measured in the test animals (mice and rats) after intraperitoneal administration of test compound 1 as described in Biological Experimental Example II. The obtained results are shown in following Table 5 and Fig. 2.
(Table 5) Duration of scPTZ test ED50(mg/kg), (ip)
Figure imgf000106_0003
As shown in Table 5 and Fig. 2, the test compound 1 exhibits the efficacy duration time of at least 12 hours in both of the tested rats and mice.
As the pharmaceutical efficacy duration time of a drug is longer, the administration number of the drug becomes decreased, thereby increasing the administration convenience of a patient. Such advantages may be particularly preferable for a patient suffered from a disease that requires long term administration of a drug, such as epilepsy. In addition, the decrease of the administration number may be profitable in economic aspect and helpful to increase the quality of life of the patient.

Claims

WHAT IS CLAIMED IS:
1. A phenyl carbamate compound represented by Chemical Formula 1 :
[Chemical formula 1
Figure imgf000108_0001
wherein
X is a halogen;
n is an integer from 1 to 5;
Rl is a linear or branched alkyl group of C1-C4;
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000108_0002
H
B is hydrogen, a carbamoyl derivative represented by ® , trialkyl silyl groups, trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three), or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group is independently selected from the group consisting of C5-C8 aryl groups;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, a cycloalkyl group of C3-C8, and benzyl group.
2. The phenyl carbamate compound according to Claim 1, wherein
X is chlorine, fluorine, iodine, or bromine;
n is 1 or 2;
Rl is methyl group, ethyl group, isopropyl group, or butyl group; A is hydrogen or a carbamoyl derivative represented by
Figure imgf000109_0001
- H
B is hydrogen, a carbamoyl derivative represented by 0 , a trimethyl silyl
(TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, a t-butyl diphenyl silyl (TBDPS) group, or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 are the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
The phenyl carbamate compound according to Claim 1 , wherein the compound is selected from the group consisting of:
2-chlorophenyl )- 1 -hydroxypropyl-2-carbamate,
2-chlorophenyl )- 1 -hydroxy-3 -methyl -butyl-2-carbamate,
2-chlorophenyl )- 1 -hydroxyhexyl-2-carbamate,
2-chlorophenyl )- 1 -hydroxypropyl -2 -N-methyl carbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-propylcarbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-isopropyl carbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-cyclopropylcarbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-cyclohexylcarbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-benzylcarbamate,
2-chlorophenyl )-l -hydroxypropyl-2-N-bicyclo[2,2, 1 ]heptanecarbamate,
2,4-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
2,6-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
2,4-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate,
2,4-dichlorophenyl)- 1 -hydroxy-3 -methyl-butyl-2-carbamate,
2,6-dichlorophenyl)-l-hydroxy-3-methyl-butyl-2-carbamate, 1 -(2,4-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2,6-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-methyl carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-propylcarbamate,
l-(2-chlorophenyl)-2-hydroxypropyl-l-N-isopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-cyclopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-cyclohexyl carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl-l -N-benzyl carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxy-3-methyl-butyl- 1 -carbamate,
l-(2,6-dichlorophenyl)-2-hydroxy-3-methyl-butyl-l-carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxyhexyl-l -carbamate,
1 -(2-fluorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxybutyl-2-carbamate,
l-(2,3-dichlorophenyl)-l-hydroxypropyl-2-carbamate, and
1 -(2,
3-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate.
4. The phenyl carbamate compound according to any one of Claims 1 to 3, wherein the compound is in the form of racemate, enantiomer, diastereomer, a mixture of enantiomer, or a mixture of diastereomer.
5. A pharmaceutical composition for preventing or treating epilepsy comprising a phenyl carbamate compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, as an active ingredient:
[Chemical formula 1]
Figure imgf000111_0001
wherein
X is a halogen;
n is an integer from 1 to 5;
Rl is a linear or branched alkyl group of C1-C4;
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000111_0002
H
B is hydrogen, a carbamoyl derivative represented by O , trialkyl silyl groups, trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three), or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group is independently selected from the group consisting of C5-C8 aryl groups ;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, a cycloalkyl group of C3-C8, and benzyl group.
6. The pharmaceutical composition according to Claim 5, wherein
X is chlorine, fluorine, iodine, or bromine;
n is 1 or 2;
Rl is methyl group, ethyl group, isopropyl group, or butyl group;
^R2
A is hydrogen or a carbamoyl derivative represented by B is hydrogen, a carbamoyl derivative represented by
Figure imgf000112_0001
, a trimethyl silyl
(TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, a t-butyl diphenyl silyl (TBDPS) group, or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 are the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
7. The pharmaceutical composition according to Claim 5, wherein the compound is selected from the group consisting of:
2-chlorophenyl )- 1 -hydroxypropyl-2-carbamate,
2-chlorophenyl )- 1 -hydroxybutyl-2-carbamate,
2-chlorophenyl )- 1 -hydroxy-3 -methyl-butyl-2-carbamate,
2-chlorophenyl )- 1 -hydroxyhexyl-2-carbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-methylcarbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-propylcarbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-isopropyl carbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-cyclopropylcarbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-cyclohexylcarbamate,
2-chlorophenyl )- 1 -hydroxypropyl-2-N-benzylcarbamate,
2-chlorophenyl )-l-hydroxypropyl-2-N-bicyclo[2,2,l]heptanecarbamate,
2,4-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
2,6-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
2,4-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate,
2,6-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate,
2,4-dichlorophenyl)- 1 -hydroxy-3 -methyl-butyl-2-carbamate,
2,6-dichlorophenyl)- 1 -hydroxy-3-methyl-butyl-2-carbamate,
2,4-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate, 1 -(2,6-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl-l -N-methylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-propylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl-l -N-isopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-cyclopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl-l -N-cyclohexylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-benzyl carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxypropyl-l -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2 -hydro xybutyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxy-3 -methyl-butyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxy-3 -methyl-butyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2-fluorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxybutyl-2-carbamate,
1 -(2,3-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate, and
l-(2,3-dichlorophenyl)-2-hydroxypropyl-l-carbamate.
8. The pharmaceutical composition according to any one of Claims 5 to 7, wherein the compound is in the form of racemate, enantiomer, diastereomer, a mixture of enantiomer, or a mixture of diastereomer.
9. A phenyl carbamate compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, for the use in preventing or treating epilepsy:
[Chemical formula 1]
Figure imgf000114_0001
wherein
X is a halogen;
n is an integer from 1 to 5;
l is a linear or branched alkyl group of C1-C4;
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000114_0002
H
B is hydrogen, a carbamoyl derivative represented by 0 , trialkyl silyl groups, trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three), or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group is independently selected from the group consisting of C5-C8 aryl groups;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, a cycloalkyl group of C3-C8, and benzyl group.
10. The compound or a pharmaceutically acceptable salt thereof according to Claim 9, wherein
X is chlorine, fluorine, iodine, or bromine;
n is 1 or 2;
Rl is methyl group, ethyl group, isopropyl group, or butyl roup;
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000114_0003
H
B is hydrogen, a carbamoyl derivative represented by ® , a trimethyl silyl
(TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, a t-butyl diphenyl silyl (TBDPS) group, or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 are the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
11 The compound or a pharmaceutically acceptable salt thereof according to Claim
9, wherein the compound is selected from the group consisting of:
2-chlorophenyl)- 1 -hydroxypropyl-2-carbamate,
2-chlorophenyl)- 11 -hydroxybutyl-2-carbamate,
2-chlorophenyl)- 11 -hydroxy-3 -methyl-butyl-2-carbamate,
2-chlorophenyl)- 11 -hydroxyhexyl-2-carbamate,
2-chlorophenyl)- l 1 -hydroxypropyl-2-N-methylcarbamate,
2-chlorophenyl)- l 1 -hydroxypropyl-2-N-propylcarbamate,
2-chlorophenyl)- l-hydroxypropyl-2-N-isopropylcarbamate,
2-chlorophenyl)- l-hydroxypropyl-2-N-cyclopropylcarbamate,
2-chlorophenyl)- l-hydroxypropyl-2-N-cyclohexylcarbamate,
2-chlorophenyl)- l-hydroxypropyl-2-N-benzylcarbamate,
2-chlorophenyl)- 1 -hydroxypropyl-2-N-bicyclo[2,2, 1 Jheptanecarbamate,
2,4-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
2,6-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
2,4-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate,
2,6-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate,
2,4-dichlorophenyl)-l-hydroxy-3-methyl-butyl-2-carbamate,
2,6-dichlorophenyl)- 1 -hydroxy-3 -methyl-butyl-2-carbamate,
2,4-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate, 1 -(2,6-dichlorophenyl)-l -hydroxyhexyl-2-carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-methylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-propylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-isopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-cyclopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl-l -N-cyclohexylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-benzyl carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxy-3 -methyl -butyl- 1 -carbamate,
l-(2,6-dichlorophenyl)-2-hydroxy-3-methyl-butyl-l-carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2-fluorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxybutyl-2-carbamate,
l-(2,3-dichlorophenyl)-l -hydroxypropyl-2-carbamate, and
1 -(2,3 -dichlorophenyl)-2-hydroxypropyl- 1 -carbamate.
12. The compound or a pharmaceutically acceptable salt thereof according to any one of Claims 9 to 11, wherein the compound is in the form of racemate, enantiomer, diastereomer, a mixture of enantiomer, or a mixture of diastereomer.
13. A use of phenyl carbamate compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof in manufacturing a pharmaceutical composition for preventing or treating epilepsy:
[Chemical formula 1 ]
Figure imgf000117_0001
wherein
X is a halogen;
n is an integer from 1 to 5;
Rl is a linear or branched alkyl group of C 1 -C4;
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000117_0002
;
H
B is hydrogen, a carbamoyl derivative represented by ^ , trialkyl silyl groups, trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three), or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group is independently selected from the group consisting of C5-C8 aryl groups;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 may be the same as or-different from each other^ and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, a cycloalkyl group of C3-C8, and benzyl group.
14. The use according to Claim 13, wherein
X is chlorine, fluorine, iodine, or bromine;
n is 1 or 2;
Rl is methyl group, ethyl group, isopropyl group, or but l group;
A is hydrogen or a carbamoyl derivative represented by
Figure imgf000117_0003
H
B is hydrogen, a carbamoyl derivative represented by ® , a trimethyl silyl
(TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, a t-butyl diphenyl silyl (TBDPS) group, or a trialkyl silyl ether group, wherein each alkyl group is independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups;
A and B are not carbamoyl derivatives at same time; and
R2 and R3 are the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
15. The use according to Claim 13, wherein the compound is selected from the group consisting of:
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2-chlorophenyl)- 1 -hydroxybutyl-2-carbamate,
1 -(2-chlorophenyl)- 1 -hydroxy-3 -methyl-butyl-2-carbamate,
1 -(2-chlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-methyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-propylcarbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-isopropyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-cyclopropylcarbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-cyclohexyl carbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-benzylcarbamate,
1 -(2-chlorophenyl)- 1 -hydroxypropyl-2-N-bicyclo[2,2, 1 Jheptanecarbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2,6-dichlorophenyl)- 1 -hydroxypropyl-2-carbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate,
1 -(2,6-dichlorophenyl)- 1 -hydroxybutyl-2-carbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxy-3 -methyl -butyl -2-carbamate,
l-(2,6-dichloropheriyl)-l-hydroxy-3-methyl-butyl-2-carbamate,
1 -(2,4-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate, 1 -(2,6-dichlorophenyl)- 1 -hydroxyhexyl-2-carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-methyl carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-propylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl-l -N-isopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-cyclopropylcarbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-cyclohexyl carbamate,
1 -(2-chlorophenyl)-2-hydroxypropyl- 1 -N-benzyl carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxypropyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxybutyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxy-3-methyl -butyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxy-3 -methyl-butyl- 1 -carbamate,
1 -(2,4-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2,6-dichlorophenyl)-2-hydroxyhexyl- 1 -carbamate,
1 -(2-fluorophenyl)-l -hydroxypropyl-2-carbamate,
1 -(2-iodophenyl)- 1 -hydroxypropyl-2 -carbamate,
1 -(2-iodophenyl)- 1 -hydroxybutyl-2-carbamate,
1 -(2,3 -dichlorophenyl)- 1 -hydroxypropyl-2-carbamate, and
1 -(2,3 -dichlorophenyl)-2-hydroxypropyl- 1 -carbamate.
16. The use according to any one of Claims 13 to 15, wherein the compound is in the form of racemate, enantiomer, diastereomer, a mixture of enantiomer, or a mixture of diastereomer.
PCT/KR2012/011474 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilesy WO2013100570A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2012360365A AU2012360365B2 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilepsy
EP12862488.9A EP2797880B1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilepsy
RU2014124028A RU2632659C2 (en) 2011-12-27 2012-12-26 Phenylcarbamate compounds for application in epilepsy prevention or treatment
MX2014008020A MX353024B (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilesy.
BR112014015568-2A BR112014015568B1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds, pharmaceutical composition, and their uses in the prevention or treatment of epilepsy
KR1020147015403A KR101880584B1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilesy
CN201280070646.6A CN104136413B (en) 2011-12-27 2012-12-26 For preventing or treat the carbanilate compound of epilepsy
CA2859129A CA2859129C (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilepsy
ES12862488.9T ES2624989T3 (en) 2011-12-27 2012-12-26 Phenylcarbamate compounds for use in the prevention or treatment of epilepsy
JP2014549995A JP6298766B2 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in the prevention or treatment of epilepsy
IN1436MUN2014 IN2014MN01436A (en) 2011-12-27 2014-07-15

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161580409P 2011-12-27 2011-12-27
US61/580,409 2011-12-27

Publications (1)

Publication Number Publication Date
WO2013100570A1 true WO2013100570A1 (en) 2013-07-04

Family

ID=48655156

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/KR2012/011474 WO2013100570A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating epilesy
PCT/KR2012/011472 WO2013100569A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating multiple sclerosis
PCT/KR2012/011469 WO2013100566A1 (en) 2011-12-27 2012-12-26 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
PCT/KR2012/011470 WO2013100567A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
PCT/KR2012/011471 WO2013100568A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating stroke
PCT/KR2012/011475 WO2013100571A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating als

Family Applications After (5)

Application Number Title Priority Date Filing Date
PCT/KR2012/011472 WO2013100569A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating multiple sclerosis
PCT/KR2012/011469 WO2013100566A1 (en) 2011-12-27 2012-12-26 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
PCT/KR2012/011470 WO2013100567A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
PCT/KR2012/011471 WO2013100568A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating stroke
PCT/KR2012/011475 WO2013100571A1 (en) 2011-12-27 2012-12-26 Phenyl carbamate compounds for use in preventing or treating als

Country Status (13)

Country Link
US (6) US9029589B2 (en)
EP (6) EP2797881B1 (en)
JP (8) JP6089045B2 (en)
KR (6) KR101862203B1 (en)
CN (6) CN104870421A (en)
AU (2) AU2012360362B2 (en)
BR (2) BR112014015568B1 (en)
CA (2) CA2858977C (en)
ES (3) ES2710902T3 (en)
IN (2) IN2014MN01436A (en)
MX (2) MX338554B (en)
RU (2) RU2632659C2 (en)
WO (6) WO2013100570A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142519A1 (en) 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
EP2970110A4 (en) * 2013-03-12 2016-12-28 Bio-Pharm Solutions Co Ltd Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
RU2632659C2 (en) * 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Phenylcarbamate compounds for application in epilepsy prevention or treatment
US9937145B2 (en) * 2013-12-12 2018-04-10 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compound for use in preventing or treating epilepsy
EP3443959A1 (en) * 2013-12-12 2019-02-20 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating pain
EP3423433A4 (en) * 2016-02-29 2019-12-25 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
KR102005019B1 (en) 2018-04-04 2019-07-31 한국과학기술연구원 A composition for preventing and treating stroke
CN112567035A (en) 2018-07-02 2021-03-26 沃雅戈治疗公司 Treatment of amyotrophic lateral sclerosis and spinal cord related disorders
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
KR102427769B1 (en) 2020-08-07 2022-08-02 한국과학기술연구원 Composition for prevention or treatment of multiple sclerosis
KR102531540B1 (en) 2020-09-18 2023-05-16 한국과학기술연구원 Composition for prevention or treatment of rheumatoid arthritis
KR102614653B1 (en) 2021-06-09 2023-12-20 한국과학기술연구원 Novel heterocyclyl-phenyl-methylamine derivatives, preparation method thereof, and use thereof for preventing, improving, or treating multiple sclerosis
WO2023014160A1 (en) 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 Phenyl carbamate crystalline form and method for preparing same
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
KR102399807B1 (en) * 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 Phenylcarbamate crystalline form and method for manufacturing the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313700A (en) * 1962-07-18 1967-04-11 Armour Pharmacentical Company Method of treating the central nervous system with substituted phenethyl carbamates and compositions therefor
US3313699A (en) * 1962-06-26 1967-04-11 Armour Pharma Compositions for and method of treating the central nervous system
JPS61271992A (en) * 1985-05-28 1986-12-02 Central Glass Co Ltd Production of optically active diol
WO2008013213A1 (en) * 2006-07-28 2008-01-31 Eisai R & D Management Co., Ltd. Prodrug of cinnamide compound
WO2008124848A1 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884444A (en) 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
US2937119A (en) 1959-06-11 1960-05-17 Carter Prod Inc Nu-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamates
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265727A (en) 1962-06-26 1966-08-09 Armour Pharma Phenyl alkyl-1, 2 dicarbamates
US3313696A (en) 1962-06-26 1967-04-11 Armour Pharmacentical Company Carbamate sedative compositions and method of use
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
FR5671M (en) * 1965-04-23 1968-01-02
US3600427A (en) 1967-05-08 1971-08-17 Anthony J Verbiscar Phenyl carbamate latentiated phenethylamines
WO1994027941A1 (en) * 1993-05-25 1994-12-08 Avondale Chemical Company Process for preparing felbamate and intermediates thereto
US20010034365A1 (en) 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
DE60033050T2 (en) * 1999-11-29 2007-11-15 Mitsubishi Rayon Co., Ltd. ACETAL SULPHONATE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF A STYRENE OXIDE DERIVATIVE
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DE60220043T2 (en) 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. CARBAMATE COMPOUNDS FOR PREVENTING OR TREATING NEURODEEGENERATIVE DISORDER
ATE493125T1 (en) 2001-02-27 2011-01-15 Ortho Mcneil Pharm Inc CARBAMAT COMPOUNDS FOR TREATING PAIN
EP1381358B1 (en) 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
WO2003000247A1 (en) 2001-06-25 2003-01-03 Sk Corporation Carbamates of 2-heterocyclic-1,2-ethanediols
MXPA04000554A (en) 2001-07-16 2005-02-17 Johnson & Johnson Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain.
EE05381B1 (en) * 2001-12-21 2011-02-15 Ortho-McNeil�Pharmaceutical,�Inc. Process for the Preparation of 2- (Substituted-Phenyl) -2-H-Diacarbamates, Intermediate Compounds and Morpho-Formations of Carbamates
FR2836915B1 (en) * 2002-03-11 2008-01-11 Aventis Pharma Sa AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
AU2003263574A1 (en) 2002-05-31 2003-12-19 Patel, Hetalkumar, Virendrabhai A process for the preparation of phenylcarbamates
PT1622912E (en) * 2003-04-23 2009-08-17 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
BRPI0416268A (en) 2003-11-05 2007-12-11 Unimed Pharmaceuticals Inc delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis
MXPA06012231A (en) * 2004-04-21 2006-12-15 Schering Corp PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A.
AU2005254945C1 (en) * 2004-06-08 2013-07-11 Families Of Spinal Muscular Atrophy 2,4-Diaminoquinazolines for spinal muscular atrophy
ATE464044T1 (en) * 2004-09-16 2010-04-15 Janssen Pharmaceutica Nv USE OF 2-PHENYL-1,2-ETHANEDIOL (DI)CARBAMATES FOR THE TREATMENT OF EPILEPTOGENesis
CN101076327A (en) * 2004-10-15 2007-11-21 詹森药业有限公司 Carbamate compounds for use in treating neurodegenerative disorders
US7442438B2 (en) 2005-05-04 2008-10-28 3M Innovative Properties Company Wet and dry stick adhesive, articles, and methods
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
CN101472913A (en) * 2006-07-28 2009-07-01 卫材R&D管理有限公司 Prodrug of cinnamide compound
US7632963B2 (en) * 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
KR20090067210A (en) * 2006-10-13 2009-06-24 얀센 파마슈티카 엔.브이. Phenylalkyl carbamate compositions
AU2007319578A1 (en) 2006-10-27 2008-05-22 Janssen Pharmaceuticals, N.V. Methods for treatment of cochlear and vestibular disorders
WO2008055022A2 (en) 2006-10-30 2008-05-08 Janssen Pharmaceutica, N.V. Carbamate compounds for use in treating depression
PE20081775A1 (en) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
WO2009022345A1 (en) 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
US20090105498A1 (en) * 2007-10-18 2009-04-23 Porstmann Frank Improved process for preparing 2-(substituted phenyol)-2-hydroxy-ethyl-carbamates
CN102159077A (en) 2008-08-21 2011-08-17 吉瑞工厂 Methods for treating neuropathic pain
JP2011219387A (en) * 2010-04-06 2011-11-04 Kaneka Corp Method for producing ionic liquid
CA2803825C (en) * 2010-07-02 2015-12-29 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US9018253B2 (en) * 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
JP5838226B2 (en) * 2011-01-13 2016-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド Method for producing phenyl carbamate derivative
ES2543050T3 (en) * 2011-02-28 2015-08-14 Array Biopharma, Inc. Serine / Threonine Kinase Inhibitors
RU2632659C2 (en) * 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Phenylcarbamate compounds for application in epilepsy prevention or treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313699A (en) * 1962-06-26 1967-04-11 Armour Pharma Compositions for and method of treating the central nervous system
US3313700A (en) * 1962-07-18 1967-04-11 Armour Pharmacentical Company Method of treating the central nervous system with substituted phenethyl carbamates and compositions therefor
JPS61271992A (en) * 1985-05-28 1986-12-02 Central Glass Co Ltd Production of optically active diol
WO2008013213A1 (en) * 2006-07-28 2008-01-31 Eisai R & D Management Co., Ltd. Prodrug of cinnamide compound
WO2008124848A1 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIRIJAVALLABHAN, V. M. ET AL.: "Synthesis of the antifungal agent SCH 42427(SM 9164)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 1, no. 7, 1991, pages 349 - 352, XP055073671 *
JIAO, P. ET AL.: "A Sequential O-Nitrosoaldol and Grignard Addition Process: An Enantio- and Diastereoselective Entry to Chiral 1,2-Diols", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 48, no. 18, 2009, pages 3333 - 3336, XP055073637 *
See also references of EP2797880A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142519A1 (en) 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
EP2968210A4 (en) * 2013-03-12 2016-12-28 Bio-Pharm Solutions Co Ltd Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes
EP2970110A4 (en) * 2013-03-12 2016-12-28 Bio-Pharm Solutions Co Ltd Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
EP2968211A4 (en) * 2013-03-12 2017-01-04 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
EP2968212A4 (en) * 2013-03-12 2017-01-11 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
EP2970111A4 (en) * 2013-03-12 2017-01-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a nerve gas-induced disease comprising the same
US9682059B2 (en) 2013-03-12 2017-06-20 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
US9956197B2 (en) 2013-03-12 2018-05-01 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndromes

Also Published As

Publication number Publication date
IN2014MN01436A (en) 2015-07-03
CN104136416B (en) 2016-11-09
EP2797879A4 (en) 2015-10-07
US20130184338A1 (en) 2013-07-18
KR20140113919A (en) 2014-09-25
WO2013100566A1 (en) 2013-07-04
US20130203846A1 (en) 2013-08-08
JP2018108996A (en) 2018-07-12
RU2014124029A (en) 2016-02-20
US9162975B2 (en) 2015-10-20
JP6155280B2 (en) 2017-06-28
CN104136413A (en) 2014-11-05
AU2012360365B2 (en) 2017-08-31
BR112014015568A2 (en) 2017-06-13
EP2797878B1 (en) 2017-08-16
EP2797880A4 (en) 2015-10-07
CN104136413B (en) 2016-10-26
BR112014015568B1 (en) 2022-03-29
CN104169253B (en) 2016-11-09
BR112014015568A8 (en) 2017-07-04
RU2014124028A (en) 2016-02-20
BR112014015482A2 (en) 2017-06-13
JP2015504053A (en) 2015-02-05
KR101795562B1 (en) 2017-11-08
BR112014015482A8 (en) 2017-07-04
CN104136415A (en) 2014-11-05
WO2013100566A8 (en) 2014-02-20
EP2797880B1 (en) 2017-03-01
CA2859129C (en) 2020-07-14
EP2797878A4 (en) 2015-10-07
MX2014008021A (en) 2014-08-01
KR101795563B1 (en) 2017-11-08
AU2012360362B2 (en) 2017-08-31
AU2012360362A1 (en) 2014-08-07
US20130165410A1 (en) 2013-06-27
EP2797876A4 (en) 2015-10-07
ES2624989T3 (en) 2017-07-18
JP6298766B2 (en) 2018-03-20
ES2710902T3 (en) 2019-04-29
KR20140108226A (en) 2014-09-05
AU2012360365A1 (en) 2014-08-07
CA2859129A1 (en) 2013-07-04
KR101862203B1 (en) 2018-05-29
EP2797881A1 (en) 2014-11-05
KR101880584B1 (en) 2018-07-20
CN104136416A (en) 2014-11-05
JP2015503550A (en) 2015-02-02
CN104169253A (en) 2014-11-26
WO2013100571A9 (en) 2014-09-18
CN104136414A (en) 2014-11-05
WO2013100567A1 (en) 2013-07-04
ES2716832T3 (en) 2019-06-17
MX338554B (en) 2016-04-20
US9029589B2 (en) 2015-05-12
KR20150023217A (en) 2015-03-05
MX2014008020A (en) 2014-12-08
EP2797877A1 (en) 2014-11-05
KR20140113918A (en) 2014-09-25
JP2015506934A (en) 2015-03-05
EP2797881B1 (en) 2018-11-14
WO2013100571A1 (en) 2013-07-04
US9624164B2 (en) 2017-04-18
EP2797876A1 (en) 2014-11-05
EP2797879A1 (en) 2014-11-05
KR20140108245A (en) 2014-09-05
JP2015508398A (en) 2015-03-19
US9034848B2 (en) 2015-05-19
US20130165408A1 (en) 2013-06-27
JP2015504055A (en) 2015-02-05
US20130165409A1 (en) 2013-06-27
EP2797878A1 (en) 2014-11-05
US20130165509A1 (en) 2013-06-27
WO2013100568A1 (en) 2013-07-04
EP2797877A4 (en) 2015-10-07
EP2797880A1 (en) 2014-11-05
CA2858977C (en) 2020-06-23
RU2632659C2 (en) 2017-10-09
JP6298765B2 (en) 2018-03-20
MX353024B (en) 2017-12-18
CN104136415B (en) 2016-09-07
JP2017193577A (en) 2017-10-26
EP2797881A4 (en) 2016-01-13
JP6089045B2 (en) 2017-03-01
CN104870421A (en) 2015-08-26
EP2797879B1 (en) 2018-12-26
JP2015504054A (en) 2015-02-05
KR20140113914A (en) 2014-09-25
CA2858977A1 (en) 2013-07-04
WO2013100569A1 (en) 2013-07-04
WO2013100567A8 (en) 2014-02-20
IN2014MN01432A (en) 2015-07-03

Similar Documents

Publication Publication Date Title
AU2012360365B2 (en) Phenyl carbamate compounds for use in preventing or treating epilepsy
EP2968213A1 (en) Phenyl carbamate compounds for use in preventing or treating a movement disorder
WO2012096458A2 (en) Process for preparation of phenyl carbamate derivatives
EP2970110A1 (en) Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
CN104628603B (en) Carbanilate compound and the muscle relaxant containing carbanilate compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12862488

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20147015403

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2859129

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014549995

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/008020

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2012862488

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012862488

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014124028

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012360365

Country of ref document: AU

Date of ref document: 20121226

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014015568

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014015568

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140624